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ZUSAMMENFASSUNG 
 
Mitochondriopathien sind Multisystemerkrankungen die durch verschiedene Defekte in den 
Energie (ATP) produzierenden Stoffwechselwegen der Mitochondrien verursacht sind. Will 
man Mitochondriopathien auf molekularer Ebene diagnostizieren, stößt man auf folgende 
Schwierigkeiten: (A) Ungefähr 1000 Gene sind an der Biogenese des Mitochondriums 
beteiligt. Die Dysfunktion jedes einzelnen dieser Gene kann potentiell zur Mitochondriopathie 
führen. (B) Mitochondriale Proteine werden durch zwei Genome, durch die mitochondriale 
und durch die nukleäre DNA kodiert. (C) Die klinischen Symptome der Patienten weisen 
selten auf die molekulare Diagnose, da der Phänotyp oft nur auf einem sekundären 
Energiemangel beruht. In der Regel besteht keine sichere Genotyp-Phänotyp-Relation. 
Mit den gegenwärtig zur Verfügung stehenden Methoden lassen sich bei nur 20% der 
Patienten Mutationen finden. Wir wollten daher eine neue Screening-Methode entwickeln, 
mit deren Hilfe wir hoffen, die Aufspürungsrate für mitochondriale Mutationen zu erhöhen. 
Die Gesamtheit der Proteine einer Organelle oder einer ganzen Zelle (ihr “Proteom”) stellt das 
Verbindungsglied zwischen Geno- und Phänotyp dar. Aus diesem Grunde wollten wir das 
mitochondriale Proteom von gesunden Kontrollpersonen und von Patienten mit 
Mitochondriopathien untersuchen. Protein-Muster, die zwischen diesen beiden Gruppen 
abweichen, könnten die Aufmerksamkeit auf Gene und Proteine richten, die an der 
Entstehung des Krankheits-Phänotyps beteiligt sind. Um solch eine vergleichende Studie 
durchzuführen, muß zunächst eine Referenzkarte des normalen mitochondrialen Proteoms 
erstellt werden. In meinem Dissertationsprojekt habe ich diese grundlegende Arbeit 
durchgeführt und zahlreiche Proteine auf der Proteomkarte menschlicher Mitochondrien 
identifiziert, die aus Epstein-Barr-Virus-transformierten lymphoblastoiden Zellen gewonnen 
worden waren. Ich wählte diese Zellsorte als Untersuchungsmaterial, da sie nicht nur einfach 
von Patienten gewonnen werden, sondern auch potentiell permanent wachsen kann. Dies 
erlaubt die Züchtung einer hohen Zellzahl ohne übermäßigen Aufwand. Ich optimierte ein 
Protokoll zur Zentrifugation in einem hybriden Gradienten, mit dem genug gereinigte 
Mitochondrien aus 108 Zellen gewonnen werden konnten. Für die Referenzkarte benutzte ich 
die lymphoblastoide Zellline einer gesunden Kontrollperson.  
Die Methode der Wahl zur Proteinidentifikation in Proteom-Projekten ist die 
zweidimensionale Proteinelektrophorese gekoppelt mit der MALDI-TOF-
Massenspektrometrie. Ich entdeckte mehr als 400 Punkte in meinem silbergefärbten 
zweidimensionalen Gel und analysierte die 141 stärksten Punkte nach in-gel Trypsin-Verdau 
VI 
 und anschließender MALDI-TOF-Massenspektrometrie in einem Verfahren, das als “Peptide 
Mass Fingerprinting” (Peptidmassen-Fingerabdruck) bezeichnet wird. Mit Hilfe 
entsprechender Datenbanken konnte ich schließlich 115 verschiedene Proteinpunkte 
(entsprechen 95 verschiedenen Proteinen) identifizieren. 90 dieser Punkte (entsprechend 74 
verschiedenen Proteinen) waren sicher mitochondrialer Herkunft und sind Komponenten aller 
wesentlichen im Mitochondrium lokalisierten Stoffwechselwege. 16 der 74 identifizierten 
mitochondrialen Proteine gehören zur Atmungskette. Obwohl 18 mitochondriale Proteine in 
der Datenbank SWISS-PROT als “Membran-assoziiert” annotiert sind, identifizierte ich nur 
vier Proteine mit sicheren Transmembrandomänen. Ich entdeckte keine der 13 durch die 
mitochondriale DNA kodierten Proteine, die alle stark hydrophobe Membranproteine sind. 
Andere Forscher sind bei dem Versuch diese Proteine zu identifizieren, auf die gleichen 
Schwierigkeiten gestoßen. 
Mit meiner Dissertationsarbeit habe ich unsere eigene Datenbank und Referenzkarte des 
mitochondrialen Proteoms lyphoblastoider Zellen erstellt. Diese Daten ermöglichen nun die 
Analyse des mitochondrialen Proteoms von Patienten. Meine weiteren Untersuchungen auf 
diesem Gebiet werden sich nun auf die genetische Variabilität des Proteoms gesunder 
Kontrollpersonen und auf das Proteom der Patienten mit Mitochondriopathien beziehen. 
 
Schlüsselwörter: Mitochondrien, Proteom, Dichtegradientenzentrifugation, 
zweidimensionale Proteinelektrophorese, Proteinidentifikation, MALDI-TOF 
Massenspektrometrie, Peptidmassen-Fingerabdruck. 
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ABSTRACT 
 
Mitochondrial disorders are multisystem diseases that can be caused by any defect in the 
energy (ATP) generating pathways in the mitochondria. The difficulty in diagnosing 
mitochondrial diseases on the molecular level arises from several obstacles: (A) About 1000 
genes are involved in the biogenesis of mitochondria. The dysfunction of each of them may 
potentially cause mitochondriopathy. (B) The mitochondrial proteins are encoded by two 
genomes: the mitochondrial DNA and the nuclear DNA. (C) The clinical symptoms of the 
patients rarely suggest a molecular diagnosis since in most cases, the phenotype is a 
secondary phenomenon to energy depletion. Generally there is no genotype-phenotype 
relation. 
Based on current diagnostic methods in only 20% of the patients a mutation can be found. We 
therefore wanted to develop a new screening method by which we hope to increase the identi-
fication rate. Since the numerous proteins of an organelle or of a whole cell (its “proteome”) 
connect the genotype with the phenotype, we set out to study the proteome of the mitochon-
drion in healthy individuals and in patients with mitochondrial diseases. Deviating protein 
patterns between the two individuals could direct the attention to disease-specific proteins and 
genes, which might be involved in the expression of a disease-phenotype. In order to perform 
such a comparison I first had to establish a normal reference map. In my dissertation project I 
performed this basic task and identified numerous mitochondrial proteins on the proteome-
map of human mitochondria, which had been extracted from lymphoblastoid cells. I selected 
Epstein-Barr-Virus-transformed lymphoblastoid cells as samples not only because they are 
easily obtained from patients, but also due to their potential permanent growth. This approach 
allows the cultivation of high cell numbers without excessive expenditure of work and cost. I 
optimized a protocol for hybrid gradient centrifugation, by which enough mitochondria can be 
purified from 108 cells. I used a cultured lymphoblastoid cell line from a normal control pa-
tient and isolated mitochondria from it by using hybrid gradient centrifugation. In proteomics 
the combination of the high-resolution two-dimensional electrophoresis and matrix assisted 
laser desorption/ionization–time–of–flight–mass spectrometry (MALDI-TOF-MS) is cur-
rently the method of choice for protein identification. I detected more than 400 spots in a sil-
ver-stained two-dimensional gel. I analyzed the 141 strongest spots of it by trypsin in gel di-
gestion and subsequent MALDI-TOF mass spectrometry in a process termed “peptide mass 
fingerprinting”. After database search, I finally identified 115 protein spots (corresponding to 
VIII 
 95 different proteins), 90 of which (corresponding to 74 different proteins) are of confirmed 
mitochondrial origin. These identified proteins are components of the main biological path-
ways located in the mitochondrion. 16 of the 74 identified mitochondrial proteins belong to 
the respiratory chain. Despite the fact that 18 mitochondrial proteins are annotated in the 
SWISS-PROT-database as “membrane associated proteins”, only four of them have clear 
transmembrane domains. None of the proteins encoded by the mitochondrial DNA could be 
detected. All of them are hydrophobic membrane proteins. A similar difficulty in resolving 
riation of the proteome of healthy individuals and on patients with mitochondrial 
iseases.  
is, protein identification, MALDI-TOF mass spectrometry, peptide 
ass fingerprinting. 
 
these proteins was encountered by other research groups.  
With my dissertation I established our own database and reference map of the mitochondrial 
proteome of lymphoblastoid cells. These data will facilitate the analysis of the mitochondrial 
proteome in patients. My future research based on this dissertation will mainly focus on the 
genetic va
d
 
Keywords: mitochondria, proteome, density gradient centrifugation, two-dimensional 
protein electrophores
m
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1 INTRODUCTION  
 
1.1 Introduction to mitochondria 
 
1.1.1 Mitochondrial morphology, biogenesis and composition 
 
Mitochondria are essential cell organelles in the cytoplasm which have a double-membrane. 
They are thought to have arisen about 1.5 billion years ago and to originate from a symbiotic 
association between oxidative bacteria and glycolytic proto-eukaryotic cells [Margulis, 1974]. 
“Modern” mitochondria retain a number of features that reflect their endosymbiotic origin. 
These include the double membrane structure and a bacteria-like circular mitochondrial 
genome with mitochondria-specific transcription, translation, and protein assembly systems 
[Margulis, 1974; Gray et al., 1999; Lopez et al., 2002].  
Mitochondria are made up of two highly specialized membrane systems. These are the inner 
and the outer membranes. In the center of the mitochondrion and between the membranes 
there are two aqueous compartments: the matrix and the inter-membrane space [Frey et al., 
2000]. The two membrane systems contain carrier proteins and channels that regulate the 
exchange of substrates between the compartments. The inner membrane is especially rich in 
proteins, e.g. the high molecular weight multi-protein-complexes of the respiratory chain are 
located at the inner mitochondrial membrane. The total number of different proteins or 
polypeptides making up a mitochondrion is estimated to be around 1000 [Lopez et al., 2002].  
 phosphate.  
 
1.1.2 Functions of the mitochondria 
 
Mitochondria serve many important functions for the cell. These are the oxidative ATP-
production, the degradation of fatty acids, the modulation of intracellular calcium homeostasis 
and a major role in cell signaling and apoptosis, as well as biosynthesis (e.g. heme-groups, 
nucleotides, and amino acids) and degradation (e.g. urea cycle) of metabolites [Lopez et al., 
2002]. Below I describe the functions of the mitochondria shortly: 
 
1.1.2.1 Oxidative phosphorylation 
 
The oxidative phosphorylation takes place in the mitochondrion and is the main pathway of 
oxidative ATP-production in animals, plants and many forms of microbial life (e.g. yeast). 
One mole ATP hydrolyzes into one mole ADP and inorganic phosphate with concomitant 
release of 3054 Joules. This free energy can be made available to all cellular compartments 
that take up ATP. Most mammalian cells rely on the ATP produced this way for survival and 
anabolism [Grossman et al., 1996]. The respiratory chain-oxidative phosphorylation system 
consists of five multi-subunit enzyme complexes [Smeitink et al., 2001]. Mitochondrial 
complexes I, III and IV function as proton pumps to generate an electro-chemical gradient 
across the inner membrane. This proton gradient is then utilized by the ATP-synthase 
(complex V) to generate ATP from ADP and inorganic
 
1.1.2.2 β-Oxidation 
 
The carnitine-dependent transport of fatty acids and their β–oxidation is another important 
metabolic pathway located in the mitochondrion. Most of the fatty acids to be oxidized for 
energy production by intra-mitochondrial β-oxidation have to be transported from the cytosol 
into the mitochondrion. For transport, the fatty acids are first esterified with Coenzyme A 
(CoA) for “activation”, and are then coupled to carnitine to transverse the mitochondrial dou-
1 
 ble membrane. All enzymes of the β-oxidation are mitochondrial enzymes [Stryer, 1995; 
Kerner et al., 2000]. Acetyl-CoA, NADH, and FADH2, which are generated in each round of 
fatty acid oxidation, will later be channeled either into the citric acid cycle or directly into the 
respiratory chain to produce ATP. 
 
1.1.2.3 Citric acid cycle 
 
The citric acid cycle, also named the “Krebs’ cycle” or “tricarboxylic acid cycle”, is located in 
the mitochondrion too. This is the final common pathway for different metabolites such as 
carbohydrates, fatty acids and amino acids. The details of this cycle are shown in Fig. 1-1. 
The compounds with a high redox-potential [reduced nicotinamide-adenine-dinucleotide 
(NADH) and reduced flavin-adenine-dinucleotide (FADH2)], which are generated in this 
cycle, are later delivered to the respiratory chain of the mitochondrion in order to generate 
ATP. 
 
 
 
 
 
 
 
 
Fig. 1-1: The citric acid cycle is the final common pathway for the oxidation of fuel molecules. Most fuel
molecules enter the cycle as acetyl-CoA. The cycle starts with the fusion of oxaloacetate and acetyl-CoA to 
citrate. Citrate then undergoes a series of isomerisation-, oxidation-, and decarboxylation-steps that finally 
regenerate oxaloacetate. The free energy of these intermittent steps is used for the reduction of three 
molecules NAD+ and one molecule FAD+. The NADH- and FADH2-molecules thus generated, are 
subsequently delivered to the respiratory chain of the mitochondrion to generate ATP. 
 
1.1.2.4 Urea cycle 
take place [Krebs et al., 1932; Katunuma et al., 1966]. The 
etails of this cycle are shown in Fig. 1-2. 
 
 
The urea cycle has a role in the degradation of amino acids. It is partially located in the 
mitochondria of liver cells. In this pathway ammonia is detoxified, which is a by-product of 
amino acid catabolism. The cycle comprises four reactions and enzyme systems. The first 
reaction, the formation of citrulline from ammonia and ornithine, takes place in the matrix of 
the mitochondrion. Citrulline is then exported from the mitochondrion to the cytosol, where 
the other steps of the urea cycle 
d
2 
 1.1.2.5 Heme biosynthesis 
 
Heme, which is needed as a prosthetic group in several important proteins such as 
hemoglobin, myoglobin and cytochrome C, is partly synthesized in the mitochondrion. The 
condensation of succinyl-CoA and glycine to δ−aminolevulic acid is the key-step of the 
heme-synthesis and takes place in the mitochondrion. δ−Aminolevulic acid is then delivered 
into the cytosol where coproporphyrinogen III is formed after a series of reactions. This 
molecule later returns into the mitochondrion to be converted into heme. The details of this 
process are depicted in Fig. 1-3. 
  
 
 
 
Fig. 1-2: The urea cycle is part of the degradation pathway of amino acids. It converts the NH4+ generated by
amino acid degradation into urea. The first reaction of the urea cycle ⎯ the condensation of ornithine and
carbamaylphosphate - takes place in the mitochondrial matrix. Citrulline is then exported into the cytosol.  
 
 
 
 
Fig. 1-3: The heme biosynthesis occurs partly in the mitochondrion and partly in the cytoplasm. The first
step (the condensation of succinyl-CoA and glycine to δ−aminolevulic acid) and the final two steps
(production of heme) take place in the mitochondrion. Most of the intermediate steps take place in the
cytoplasm. 
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 1.1.2.6 Apoptosis 
 
In recent years mitochondria have been discovered to be able to initiate apoptosis by the 
release of several mediators like cytochrome c and apoptosis-inducing factor. These mediators 
activate the caspase family proteases which result in apoptosis [Osiewacz, 1997; Green et al., 
1998]. 
 
Beyond that there are still other biochemical pathways located in the mitochondrion such as 
pathways for iron metabolism and for calcium signaling. Recent findings also indicate that 
mitochondria appear to be responsible for functional age-related impairments of human 
tissues and organs [Osiewacz, 2002] and may influence cellular mechanisms and pathways 
located in the cytosol such as insulin secretion [Green et al., 1998]. 
sole et al., 2000].  
 
1.1.3 Mitochondrial genetics 
 
Each mitochondrion contains up to 10 copies of mitochondrial DNA (mtDNA). The mtDNA, 
which was completely sequenced in 1981 [Anderson et al., 1981], is a 16.56 kbp circular and 
double-stranded molecule. It encodes 13 polypeptides, 12S and 16S rRNA and 22 transfer-
RNAs. All of these products are essential for the formation of a functional mitochondrion. All 
13 polypeptides encoded by the mtDNA are components of the respiratory chain complexes. 
However, the total number of polypeptide subunits of all five mitochondrial respiratory 
complexes exceeds 88 [Lestienne, 1992; “Neuromuscular Disease Center” (see list of internet 
sites)]. Four of five enzyme complexes of the respiratory chain-oxidative phosphorylation 
system are encoded by both the nuclear DNA and the mtDNA. Only complex II (succinate: 
ubiquinone oxidoreductase; SDH) is made up exclusively of four nuclear encoded 
polypeptides. Seven of the 43 subunits of complex I (NADH: ubiquinone oxidoreductase), 
one of the eleven subunits of complex III (ubiquinol: cytochrome c oxidoreductase), three 
subunits of 13 subunits of complex IV (cytochrome c oxidase; COX), and two membrane 
components of complex V (adenosine triphosphate (ATP) synthase) are encoded by the 
mtDNA [Pe
 
The genetics of vertebrate mtDNA is characterized by these unique features:  
 
• Maternal inheritance: This means that only the mtDNA of the oocyte can be transmitted 
to the offspring [Giles et al., 1980]. With very rare exceptions the sperm mtDNA does not 
contribute to the fetus [Gustafson et al., 2002].  
• Heteroplasmy and threshold effect: The term heteroplasmy means that two populations 
of mtDNA - the wild type and the mutation type - coexist in an individual, in an organ or 
even in a single cell. Since deleterious mtDNA-mutations usually affect only parts of the 
mtDNA copies, the disease phenotype will only be expressed if the number of the mutant 
gene copies surpasses a certain threshold.  
• High mutation rate: mtDNA is thought to be vulnerable due to its compact structure, its 
lack of histone protection, its insufficient repair mechanisms and its exposure to reactive 
oxygen species generated along the respiratory chain. This vulnerability results in a high 
mutation rate, about 10-20 fold higher than that of the nuclear DNA [Osiewacz, 1997; 
Zeviani et al., 1998; DiMauro, 2000].  
 
Therefore, in inherited mitochondrial diseases the genetic defect might reside in the mito-
chondrial DNA or in the nuclear DNA. For example, in the former case the inheritance pattern 
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 is maternal, while it might be autosomal or X-chromosomal recessive or autosomal dominant 
in the later case. 
 
1.1.4 Mitochondrial disorders 
 
1.1.4.1 Definition of mitochondrial disorders 
 
Traditionally, the term “mitochondrial disorders” describes defects in the energy-generating 
apparatus of the mitochondrion, i.e. the respiratory chain coupled to the oxidative 
phosphorylation [Bauer et al., 1999]. Mitochondrial disorders comprise a heterogeneous 
group of clinical phenotypes, which can result from mutations in the mtDNA, the nuclear 
DNA or both. Abnormalities of the electron transport and the oxidative phosphorylation 
system are probably the most common causes of mitochondrial disorders [Schapira et al., 
1999]. However, mitochondrial diseases can also result from defects in metabolic pathways 
located only partially in the mitochondria (e.g. the pyruvate-dehydrogenase-complex 
deficiency). Mitochondrial disorders may manifest themselves at any time of life, from 
infancy to late adulthood. They may affect virtually any tissue either alone or in combination. 
Tissues with high energy-requirements such as heart, muscles, brain, kidney and endocrine 
organs are most commonly affected [Lopez, 2002].  
 DNA). 
taxia. 
03220)]. 
iency.  
.  
 
1.1.4.2 Classification of mitochondrial disorders 
 
The first mitochondrial disease that was understood at the molecular level was Leber’s 
hereditary optic neuropathy (LHON) with a mutation in a mtDNA encoded subunit of 
complex I [Wallace et al., 1988] and the Kearns-Sayre syndrome with a large deletion in the 
mtDNA [Holt et al., 1988]. The current classification of mitochondrial disorders is based on 
the kind and the location of the genetic defect (mtDNA versus nuclear
 
1.1.4.2.1 Mutations in the mtDNA  
 
• Large-scale duplications or deletions of the mtDNA: three main clinical syndromes are 
associated with large-scale rearrangements of the mtDNA. They are : 
 
Kearns-Sayre syndrome (OMIM 530000): this is a mitochondrial encephalomyopathy 
defined by the triad of progressive external ophthalmoplegia (PEO), pigmentary 
retinopathy and conduction block of the heart plus either the increase of cerebral 
spinal fluid protein (above 100 mg/dl) or cerebellar a
CPEO: this is a syndrome with chronic progressive external ophthalmoplegia that 
manifests itself mostly in adult patients. Since the etiology is not homogenous, several 
gene defects could lead to CPEO, such as mtDNA-deletions (OMIM 157640) or 
mutations in nuclear genes [POLG (OMIM 174763) and ANT1 (OMIM 1
Pearson syndrome (OMIM 557000): also termed Pearson’s bone marrow-pancreas 
syndrome, it is a rare disorder of early infancy. It is characterized by sideroblastic 
anemia with pancytopenia and exocrine pancreatic insuffic
 
Additionally, large-scale rearrangements of mtDNA were occasionally reported in patients 
with hypoparathyroidism, growth hormone deficiency and infertility [Folgero et al., 1993; 
Wilichowski et al., 1997; Boles et al. 1998]. Somatic mtDNA deletions have also been 
detected in various tumors [Polyak et al., 1998; Leonard et al., 2000a]
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 • Point mutations of the mtDNA: can be subdivided into missense mutations that affect (A) 
the rRNA or tRNA-genes and that (B) one of the 13 protein-encoding genes.  
 
A) tRNA- and rRNA-mutations have a global effect on mitochondrial protein synthesis. 
Until now, approximately 69 different mutations in 18 out of the 22 tRNA-genes of 
the mtDNA have been reported [MITOMAP]. Some of the mutations are associated 
with neurological syndromes such as the mitochondrial encephalomyopathy with 
lactic acidosis and stroke-like episodes (=MELAS syndrome; caused by a 
tRNALeu(UUR) mutation; OMIM 540000) and myoclonic epilepsy with ragged-red 
fibres (=MERRF syndrome; caused by a tRNALys mutation; OMIM 545000). Patients 
with mtDNA-mutations have a wide phenotypic variability. The “classic” 3243A>G 
point mutation in the mitochondrial encoded tRNALeu(UUR), which is known mainly as 
the “MELAS-mutation” might also cause other clinical symptoms such as 
cardiomyopathy, CPEO, myoclonic epilepsy and maternally inherited diabetes with 
deafness. On the other hand, the MELAS syndrome can also be caused by several 
other nucleotide exchanges within mitochondria encoded tRNA-genes, such as 
mutations at the mtDNA-nucleotides 3252, 3256, 3271, and 3291 [MITOMAP].  
it gene. 
as follows: 
up. 
 
B) Point-mutations of the mtDNA that affect genes which encode polypeptides. These 
mutations may cause: 
 
Leber’s hereditary optic neuropathy (LHON; OMIM 535000): it is characterized 
by bilateral, acute or sub-acute loss of central vision due to optic atrophy. A total 
of 17 mtDNA-mutations is known to be associated with LHON [Wallace et al., 
1999]. However, the primary LHON mutations affect subunits of complex I.  
Neuropathy, ataxia, and retinitis pigmentosa (NARP; OMIM 551500): this 
maternally inherited, adult-onset syndrome is caused by a point mutation at 
position 8993 in the mtDNA-encoded ATP synthase 6 subun
 
1.1.4.2.2 Mutations in the nuclear DNA 
 
The second group of mitochondrial disorders is due to mutations in nuclear genes. These 
mutations may affect structural subunits of the respiratory chain, their assembly, the 
replication of the mtDNA and the transport of polypeptides through the mitochondrial double 
membrane [Zeviani et al., 1999; Leonard et al., 2000b; Sue et al., 2000; Orth et al., 2001]. 
These gene defects can be grouped 
 
• Mutations in structural genes: The most common mitochondrial disorder of this group is 
Leigh syndrome, i.e. infantile sub-acute necrotizing encephalomyelopathy that is thought 
to be caused by a severe failure of energy production in the developing brain. Several 
different defects of mitochondrial enzyme complexes including pyruvate dehydrogenase 
complex (PDHc) and respiratory chain complexes I, II, IV, and V can lead to Leigh 
syndrome. Other diseases such as hereditary spastic paraplegia (progressive weakness 
and spasticity of the lower limbs; OMIM 602783) with mutations in the PARAPLEGIN-
gene also fall into this gro
• Mutation in assembly genes: SURF1, SCO1 and 2 and COX10 are assembly proteins of 
complex IV [Tiranti et al., 1998; Petruzzella et al., 1998; Papadopoulou et al., 1999]. 
Mutations in these genes can lead to Leigh syndrome and in some cases to hypertrophic 
cardiomyopathy. 
• Mutations in genes involved in mitochondrial nucleotide metabolism: Mutations in these 
genes (ANT1, TP, TWINKLE) disturb the mtDNA-replication leading to multiple deletions 
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 of the mtDNA. Such patients suffer from a mitochondrial neurogastrointestinal en-
cephalomyopathy (MNGIE; OMIM 603041) or the autosomal dominant progressive 
external ophthalmoplegia (adPEO; OMIM 103220). 
• Mutations in genes involved in mitochondrial iron hemostasis: Friedreich’s ataxia, an 
autosomal recessive disease with cerebral ataxia, peripheral neuropathy and hypertrophic 
cardiomyopathy (OMIM 229300) is due to the deficiency of frataxin, which is a 
mitochondrial protein functioning in the iron-metabolism. Additionally the X-linked 
sideroblastic anaemia with ataxia (OMIM 301310) that is caused by the defects of the 
ABC7-gene (ATP-binding cassette, transporter 7) also belongs to this group.  
hich mutations have been described before. 
• Mutations in transmembrane transport proteins: The only known disease of this type is 
the X-linked deafness-dystonia (Mohr-Tranebjaerg) syndrome that is caused by a 
mutation of a mitochondrial protein (TIM8) that functions as a transporter for peptides 
through the mitochondrial double membrane. 
 
1.1.4.3 Diagnosis of mitochondrial disorders 
 
The diagnosis of mitochondrial disorders has to rely on the sum of clinical, morphological, 
biochemical, and molecular genetic investigations since there is no explicit relation between 
genotype and phenotype. Atypical clinical pictures can be observed quite frequently in 
mitochondrial disorders. With the exception of typical syndromes like MELAS or MERRF, 
histological studies of muscle biopsy specimens are usually recommended in suspected cases. 
Characteristic changes include the presence of paracrystalline mitochondrial inclusions, 
mitochondria with abnormal size and shape, ragged-red-fibres (RRFs) in muscle, fat deposits 
and histochemically focal enzyme deficiencies (e.g. patchy COX-deficiency or SDH-
deficiency) [Zeviani et al., 1998; Parker, 2000]. In most cases, however, biochemical analysis 
have to be performed in order to formulate a diagnosis [Letellier et al., 2000]. Using 
enzymatic tests, the activities of pyruvate dehydrogenase complex (PDHc), carnitine-
palmitoyl-transferase and all complexes of the respiratory chain-oxidative phosphorylation 
system can be determined in muscle homogenate. Single enzyme activities can also be 
measured in cultured fibroblasts and in blood cells (lymphocytes and platelets). But only the 
molecular genetic analysis can verify the diagnosis of a mitochondrial disorder. In the case of 
a maternal inheritance pattern the investigations will focus on the analysis of the mtDNA. 
Otherwise, the biochemical results may narrow possible candidate genes to screen for 
mutations. For example, in the case of an isolated complex I deficiency, one would at first 
sequence the structural subunits of complex I in w
  
1.1.5 Characteristics of mitochondrial proteins and preproteins 
 
It is estimated that the mitochondrial proteome consists of approximately 1000 distinct pro-
teins [Lopez et al., 2002]. With the exception of 13 proteins, which are encoded by the 
mtDNA, most mitochondrial proteins are encoded by nuclear genes, including most of the 
mitochondrial OXPHOS proteins, the metabolic enzymes, the DNA and RNA polymerases, 
the ribosomal proteins, and the mtDNA regulatory factors [Grivell et al., 1988; Wallace, 
1999]. These proteins are synthesized at the encoplasmatic reticulum and are later imported 
into the mitochondrion. Fig. 1-4 depicts this principle of the transportation of the preproteins 
through the double membrane. Before being transported into the mitochondrion, proteins are 
synthesized as preproteins, i.e. precursors that contain transit sequences either as amino-
terminal targeting pre-sequences, or as targeting and sorting information sequences within the 
mature proteins. The cytosolic preproteins are imported through the translocases of the outer 
membrane (TOM) when their targeting information is recognized by the receptors of TOM. 
They are then sorted either directly to the outer membrane, the inter-membrane space or to the 
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 translocases of the inner-membrane (TIM). Preproteins with a typical amino-terminal target-
ing sequence engage the TIM17/TIM23 complex that guides preproteins into the matrix. In 
the matrix the targeting sequences are removed by the matrix-processing-protease, and the 
remaining polypeptide chains are folded by chaperones into mature proteins. Preproteins, 
which lack a targeting sequence, engage with the TIM22 complex to be inserted into the inner 
membrane [Millar et al., 1994; Shore et al., 1995; Hanson et al., 1996; Koehler, 2000]. 
 
1.2 Proteome analysis  
 
1.2.1 Definition of proteome analysis  
 
The term “proteome” was first advocated by Marc Wilkins in 1996 as a linguistic equivalent 
to “genome” which indicates all chromosomes and their genes of any cell type of a given 
organism. The proteome was defined as the entire protein complement expressed by a cell 
type, tissue or an organism [Wilkins et al., 1996]. Genome research usually refers to 
sequencing the total genomic DNA of an organism and mapping all genes within these 
sequences. In contrast, the aim of proteome research focuses on the structural and functional 
analysis of the proteome and the interaction of proteins with one another. This includes the 
isolation, identification and characterization of all proteins encoded by the genome of an 
organism.  
 
 
 
 
 
 
 
 
 
P
r
cFig. 1-4: Preprotein import pathways into the mitochondrion. Before being transported into the 
mitochondrion, proteins are synthesized as preproteins in the cytosol. They are then imported through the
translocases of the outer membrane (TOM). Preproteins with a typical amino-terminal targeting sequence 
engage with the inner-membrane (TIM) complex 17+23 (pathway A) to be imported into the matrix. In the 
matrix the targeting sequences are removed by the matrix-processing protease to form the mature proteins. 
Preproteins, which lack a targeting sequence, engage with the TIM22 complex (pathway B) to be inserted roteome analysis could lead the way to explain the function of an organism dynamically 
ather than statically. This is important since the protein compositions and concentrations 
hange from cell type to cell type, even within sub-cellular compartments. Moreover, they 
into the inner membrane. 
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 also differ between various stages of development [Abbott, 1999]. Proteome analysis can also 
offer the opportunity to examine entire pathways, or multiple enzymatic pathways simultane-
ously [Lopez et al., 2000]. High throughput two-dimensional protein electrophoresis [Klose, 
1975; O’Farrell, 1975] coupled with peptide mass fingerprinting analysis by MALDI-TOF 
mass spectrometry [Karas et al., 1988] have become the most powerful techniques for pro-
ome analysis. 
1.2.2 Previous work on the proteome 
nt 
roteins in mitochondria isolated from a cultured neuroblastoma cell line (IMR-32) using 
 
roughput sequencing, with the exception of typical syndromes 
ke MELAS, MERRF and LHON, most cases of mitochondrial diseases are difficult to 
 
•  causes large numbers of 
neutral changes without pathogenic significance (polymorphisms). The high number of 
ight be primary (e.g. a mutated protein 
 absent or has different running characteristics) or secondary (e.g. other proteins that are up- 
or down-regulated to compensate for a mutated protein). 
te
 
 
Using two-dimensional protein electrophoresis in order to establish a whole proteome map 
was first done by Boucherie et al. (1995) in yeast. The work was extended in 1999 [Perrot et 
al., 1999]. They identified more than 400 proteins on their reference proteome map. Similar 
results have been reported by Garrels et al. (1997), Shevchenko et al. (1996b) and Maillet et 
al. (1996). Lopez et al. (2000) established a 2D-electrophoresis map of the mitochondrial 
proteome of rat liver that included ca. 70 proteins by using high–throughput automated 
equipment in combination with mini-spin affinity columns. Analysis of the human 
mitochondrial proteome has first been done by Rabilloud et al. (1998). They investigated 
human mitochondrial proteins from placenta using 2D-electrophoresis and MALDI-TOF mass 
spectrometry, complemented by protein sequencing and immunodetection. They detected ca. 
1500 spots on a silver-stained reference gel and finally identified 46 proteins [Rabilloud et al., 
1998]. Most recently, Fountoulakis et al. (2003) identified approximately 185 differe
p
similar methods. 
1.3 The aim of my study 
 
Despite the advent of high th
li
diagnose on the molecular level.  
The difficulties in making a molecular diagnosis are: 
 
• Pleiotropy: Mutations in one gene cause different phenotypes. 
• Heterogenity: Mutations in different genes cause similar phenotypes. Often there is no 
fixed relationship between genotype and phenotype. 
• Two sources of encoding genes: The gene defect may reside in two different genomes, 
the nuclear and the mitochondrial genome. 
• Genetic variability: Any dysfunction of about 1000 different gene products located in the 
mitochondrion can potentially lead to mitochondrial diseases. 
Neutral polymorphisms: The high mutation rate of the mtDNA
these polymorphisms complicates the work of genetic analysis. 
 
Until now less than 20% of mitochondrial diseases can be diagnosed on the molecular level. 
Therefore, new tools should be established in order to increase the identification rate of 
mitochondrial diseases. Since the proteome bridges the genotype with the phenotype, we 
hypothesize that mutations in mitochondrial genes encoded by the mtDNA or nuclear DNA 
cause changes on the proteome level. These changes m
is
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However, to lay a basis for these proteome analyses we first have to establish what is 
“normal”. Furthermore we have to choose a model system that guaranties purification of a 
ufficient amount of mitochondria from patients. 
 cell lines since they can be cultivated 
ermanently in order get sufficient material for analysis. 
lls) and to establish a reference map for 
e mitochondrial proteome of lymphoblastoid cells. 
se mitochondrial diseases on proteome level 
r with a combined genetic-proteomic approach. 
 
s
 
Since lymphocytes generally express the functional defects of mitochondrial enzymes, we 
chose to work on immortalized lymphoblastoid
p
 
The aim of the present study is to establish a method to purify mitochondria from as little as 
possible patient material (cultured lymphoblastoid ce
th
 
The reference map and database can be later used to compare deviating protein patterns 
between healthy and diseased individuals. This might direct the attention to disease-specific 
proteins and genes and open new ways to diagno
o
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2 THEORY OF EMPLOYED METHODS 
 
2.1 Mitochondrial isolation 
 
In order to study mitochondrial proteins, mitochondria have to be isolated first and purified 
from proteins of other cell compartments. Such a sub-fractionation allows the detection of 
those proteins which would be invisible in total cell lysates for their low-abundance [Lopez et 
al., 2000]. We selected Epstein-Barr-Virus (EBV) transformed lymphoblastoid cell line 
samples because they have several advantages compared to other biopsy specimens: they are 
easily obtained from patients and can grow permanently in liquid, non-adherent cell cultures. 
This allows the cultivation of large cell numbers without excessive work. 
 
The initial step in purifying mitochondria is to rupture the cell membrane. There are various 
methods to disrupt cells in order to release their mitochondria. They can be ground, subjected 
to osmotic shock or to ultrasonic vibration or they can be forced through a small orifice. There 
are two “classic” methods for mitochondrial isolation: 
 
• Nitrogen cavitation: this method is based on the increased solubility of nitrogen in water 
under high pressure and its abrupt reversal after pressure release. Under high pressure, 
nitrogen penetrates quickly though the cell membranes into the cytoplasm and cell 
organelles. When the pressure is released quickly, nitrogen bubbles form, thus disrupting 
the cell membrane. Nitrogen cavitation is a gentle method for cell disruption without 
shearing. This allows efficient recovery of intact mitochondria [Gottlieb et al., 2000]. 
However, the high cost for the equipment and varying results from one experiment to 
another limit its use. 
.  
e.  
trifugation. 
 
• Potter-Elvehjem glass-Teflon pestle homogenizer: this is a method that disrupts cells 
mechanically using a motor-driven teflon pestle within a tightly fitted glass-tube [Alberts 
et al., 1994]. The shearing forces between the glass wall of the tube and the pestle disrupt 
the cells. However, if this is done too often or using a too tightly fitted pestle, the 
mitochondria might be disrupted as well. Therefore, an optimum has to be established in 
regard to the type of cells, type of pestle and number of repetitive homogenizing cycles. 
The results of the disruption (e.g. the intactness of the mitochondria) should be checked 
by electron microscopy
 
The second step of mitochondrial isolation is to retrieve mitochondria from the mixture of 
subcellular components. Both differential-velocity centrifugation and density-gradient 
centrifugation are commonly used for this purpos
 
• Differential-velocity centrifugation: the different sedimentation rates of various cellular 
components make it possible to separate them by (ultra)-centrifugation in a sucrose 
solution. “Classic” cell sub-fractionation yields four major fractions: the nuclear, the 
mitochondrial, the microsomal (i.e. endoplasmatic reticulum, Golgi-apparatus, plasma 
membrane) and the cytosolic fraction [de Duve et al., 1955]. The nuclei can be pelleted at 
low speed centrifugation (1000 g), the mitochondria at medium speed (20,000 g), the 
microsomal fraction at high speed (100,000 g), and the ribosomes at very high speed 
(150,000 g) [Almeida et al., 1997; Martin et al., 1998; Harvey et al., 1999]. This method, 
however, does not yield totally pure organelle fractions. Therefore, it is coupled to a 
second purification step by equilibrium density-gradient cen
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 • Density gradient centrifugation: this method separates cellular components according to 
their density. The impure organelle fraction is layered on top of a gradient solution and 
then centrifuged for a determined time to allow each particle to migrate to an equilibrium 
position where the density of the surrounding liquid is equal to the density of the particle. 
The commonly used density gradients can be grouped as continuous and discontinuous 
density gradients. Typical continuous gradients are made of sucrose, glycerol or Percoll 
medium [Sims, 1990; Roberti et al., 1997]. The discontinuous gradients are poured as 
discontinuous Percoll gradients [Rajapakse et al., 2001] or as Percoll/metrizamide hybrid 
gradients [Madden et al., 1987; Strack et al., 2001] in order to separate mitochondria from 
other organelles by accumulating them at a certain inter-phase after centrifugation.  
 
2.2 Determination of the protein concentration 
 
Mitochondrial proteins can be separated into two main groups [Klose, 1999a]: the hydrophilic 
proteins including the proteins of the matrix and of the inter-membrane space; the 
hydrophobic proteins such as transmembrane proteins of the inner- and outer-membrane. 
Since only proteins in solution can be analyzed, several detergents and ultrasonication are 
used to solubilize the hydrophobic (membrane) proteins [Harvey et al., 1999].  
ns.  
To measure the total protein content of a sample, several protein assay methods are routinely 
used.  
• Lowry protein assay: The most commonly used one is the Lowry protein assay and its 
modified protocols [Lowry et al., 1951]. The method is based on the characteristics of the 
Folin phenol reagent, which changes color when it is reduced. However, the Lowry 
procedure is less preferable than other methods since it is subjected to more interference 
by a wide variety of chemicals and even protei
• Bradford protein assay: An accurate alternative is the Bradford assay that is based on the 
specific binding of Coomassie blue G-250 dye to proteins. Coomassie blue G-250 absorbs 
light at a wavelength of λ=595 nm. The protein concentration of the sample can thus be 
determined photometrically by comparing its absorption to a series of protein standards 
known to exhibit a reproducible linear absorption profile. Bovine serum albumin (BSA) or 
immunoglobulin G (IgG) are the most commonly used standard proteins [Bradford, 1976; 
Stoscheck, 1990].  
• Bicinchoninic acid (BCA) protein assay: In recent years a modification of the Bradford 
assay is used widely that uses bicinchoninic acid (BCA) instead of Coomassie blue G-250 
for the colorimetric detection. In alkaline medium Cu2+ is reduced to Cu+ by proteins. The 
Cu+-ions can be detected colorimetrically with high sensitivity and selectivity by a reagent 
containing BCA. The purple-colored reaction product exhibits a strong absorption at 
λ=562 nm that is linear with the protein concentration [Smith et al., 1985]. 
 
2.3 Two-dimensional electrophoresis techniques 
 
Methodical approaches to separate proteins electrophoretically by two different principles in 
order to improve resolution can be traced back to 1956 when Smithies and Poulik developed a 
two-dimensional (2D) electrophoresis technique combining filter paper electrophoresis (first 
dimension) and starch gel electrophoresis (second dimension) [Smithies et al., 1956]. In the 
following years, a number of other 2D-electrophoresis methods were developed by combining 
various electrophoretic techniques. The current modern 2D-electrophoresis technique was 
developed independently by Klose (1975) and O’Farrell (1975). They combined isoelectric 
focussing (first dimension) with SDS-polyacrylamide gel electrophoresis (second dimension). 
This method separates proteins firstly according to their isoelectric points (pI) and secondly 
according to their molecular weights (MW). Each protein can then be attributed a pI and a 
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 MW. The 2D-electrophoresis method allows the visualization of thousands of protein-spots at 
a time, even up to total of 10,000-15,000 protein spots in a single large gel [Klose et al., 
1995]. Fig. 2-1 shows the principle of the 2D-electrophoresis method.  
 
2.3.1 First dimension: isoelectric focussing 
 
Through isoelectric focussing (IEF) proteins are separated according to their isoelectric points 
(pI). The pI depicts the pH-value at which the net charge of the protein is zero. The mobility 
of a protein in an electric field depends on the sum of its positive and negative charges. When 
the net charge of the protein is zero, the protein stops migrating in the electric field. It 
focusses where the pH of the gel equals the pI of the protein. A pH gradient can be established 
by adding a mixture of ampholytes with different isoelectric points to a polyacrylamide gel. 
The protein mixture can then be loaded either on the anodic or on the cathodic end of the gel. 
Since some very basic proteins may not migrate into the gel if the proteins were loaded on the 
cathodic end of the gel, we choose to load our samples on the acid side of the IEF-gel [Klose, 
1975, 1995]. 
 
 
 
 
 
 
 
 
 
 
2
T
g
TFig. 2-1: Principle of 2D-electrophoresis. In 2D-electrophoresis a complex protein mixture can be separated
by two biochemical principles. In the first dimension isoelectric focussing (IEF) the proteins are separated
according to their isoelectric points (pI), e.g. proteins run in an electric field as long as the surrounding pH
differs from their pI. If they reach their pI, their net charge is zero and they stop running in the electric field.
In the second dimension, proteins are separated according to their molecular weights (MW) in a SDS-
polyacrylamide gel.  .3.2 Second dimension: sodium dodecylsulfate (SDS)-polyacrylamide gel 
electrophoresis  
 
he SDS-polyacrylamide gel electrophoresis (SDS-PAGE) utilizes SDS as an anionic deter-
ent. SDS forms complexes with proteins and dissociates them into their individual subunits. 
his combination leads to two results: the ratio of SDS/protein remains sufficiently constant 
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 (1.4 g SDS per gram protein). Thus the complexes have a high anionic charge density which 
is much higher than the charge density of an individual protein. Therefore the charge differ-
ence between proteins can be ignored. Due to the same charge/protein ratio at pH 8.4, all 
SDS-protein complexes migrate to the cathode if an electrical field is applied. Secondly, since 
all SDS-protein complexes have a similar cylindrical form with a constant diameter (about 1.8 
nm) but different lengths, the sizes of the proteins are directly proportional to their molecular 
weights. Thus the electrophoretic mobility of the SDS-protein complexes depends only on 
their molecular weight, i.e. the mobility of the proteins is little influenced by any individual 
protein feature such as charge or conformation [Weber et al., 1969; Laemmli, 1970].  
 
2.3.3 Staining  
 
To visualize the protein spots on the gel, the gel has to be stained. If the protein abundance is 
high (i.e. more than 100 ng), the gel can be dyed with Coomassie brilliant blue. For the 
detection of lesser protein amounts different silver staining protocols have been developed 
[Rabilloud, 1990 and 1992; Swain et al., 1995; Klose et al., 1995]. Compared to the 
commonly used Coomassie brilliant blue staining, silver staining is more sensitive and has an 
improved detection limit of 1-10 ng. Moreover, the sensitivity of silver staining can be 
improved further by the use of several sensitizers. These sensitizers act via different chemical 
mechanisms: increasing the binding of silver (sulfosalicylic acid), creating latent images of 
spots by precipitation of micro-granules of silver sulfide (sodium thiosulfate, dithiothreitol), 
promoting silver reduction (glutaraldehyde) and complexing free unbound silver cations 
(chelators). On the other hand, the silver staining techniques treat proteins with the strong 
oxidizing agent Ag+ that may cause oxidative damage to the proteins. This can lead to 
chemical modification or destruction, and subsequent protein microanalysis will be rendered 
impossible. Several sensitizing pre-treatments of the gel with glutaraldehyde, chromic acid, 
sodium thiosulfate or thimerosal could even result in covalent modifications of the proteins. 
Shevchenko et al. (1996a) have tried to solve this problem by modifying the ”classic” silver-
staining protocols. They omitted the fixation and sensitization treatment with glutaraldehyde 
that is known to attach covalently to the protein through Schiff base formation with the α- and 
ε-amino groups. Additionally they carried out the silver nitrate treatment at 4°C in order to 
minimize oxidation.  
 
2.3.4 Reproducibility 
 
Reproducibility means that if the same sample is run on two or more different two-
dimensional gels, each spot on one gel must have its corresponding spot on another gel. 
Reproducibility is influenced by many factors ranging from sample preparation, stability of 
electrophoresis conditions and temperature to gel staining and drying [Klose, 1975; O’Farrell, 
1975]. Occasionally, some single spots can change their positions within well-reproduced 
patterns. This phenomenon can be caused by some proteins with specific variable sensitive 
properties. The problem may be solved by using optimum conditions, i.e. running the same 
sample twice, side by side and by using the same batches of solutions at each step [Klose, 
1995]. The reproducibility of the 2D-electrophoresis is reliable enough that it can be used to 
detect genetic variations by demonstrating the qualitative and quantitative changes of protein 
spots [Klose, 1995; Klose et al., 2002].  
 
2.4 Protein identification methods 
 
In order to connect the information from proteome analysis to the corresponding genes, it is 
necessary to identify the protein spots. Mass spectrometry is becoming more and more impor-
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 tant in the field of protein analysis. It is proving useful for identification of proteins separated 
by two-dimensional protein electrophoresis. The particular advantage of mass spectrometry is 
that it generally requires a limited amount of material. Sometimes even femtomoles are suffi-
cient [Perrot et al., 1999]. The most commonly used technique for protein identification by 
mass spectrometry is called “peptide mass fingerprinting”. This involves the generation of 
peptides from a protein by a proteolytic enzyme such as trypsin. The masses of the ensuing 
peptides are determined by mass-spectrometry and are matched against a theoretical list of 
peptide fragments calculated from databases of known protein sequences [Pennisi, 1997; Ex-
PaSy database]. As peptide mass fingerprinting has a higher sample throughput than amino 
acid sequencing, it is especially suitable for rapid protein identification. (Fig 2-2) 
 
 
 
 
 
 
Fig. 2-2: Principle of peptide mass fingerprinting by trypsin digestion. Trypsin cleaves at the carboxylic side
of arginine and lysine residues. The sizes of the peptide fragments obtained after trypsin digestion, represent
the peptide mass fingerprint and are characteristics of each protein. 
2.4.1 Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
 
Peptide mass fingerprinting by matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry is one tool for protein identification [Fernandez et al., 
1998]. The principle of this technique is depicted in Fig. 2-3. After in-gel digestion, the 
protein is cut into several peptide fragments by proteases, such as trypsin or chymotrypsin. 
This peptide-mixture is mixed with a matrix of 2,5-dihydroxybenzoic acid or α-cyano-4-
hydroxycinnamic acid and is let to crystallize. Subsequently the surface of the peptide/matrix 
mixture is evaporated and ionized by the photons of a high-energy laser beam. The ions are 
then accelerated in an electric field and fly towards a target. The speed and therefore the time 
of flight depends on the mass/charge ratio. The time of flight can thus be used to exactly 
measure the molecular weight of each peptide fragment up to the precision of 0.1 Dalton. At 
first this method was a rather unspecific identification tool but rapidly improved with the 
advent of machines that were able to measure also high molecular weight fragments with 
sufficient accuracy. New matrix preparations and higher sensitivity led to higher sequence 
coverage [Fernandez et al., 1998]. In favorable cases a mass coverage of over 90% of the 
peptide fragments can be achieved. The high accuracy in mass determination is made possible 
by the “delayed extraction” method [Jensen et al., 1996]. Until now, bio-macromolecules with 
molecular masses up to 300 kDa can be identified by peptide mass fingerprinting [Nielsen et 
al., 2002]. This technique has been developed to an extent that high throughput analyses are 
possible, and it has a firm place for protein identification in proteomic projects (see section 
2.4.3). 
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Fig. 2-3: Principle of MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass
spectrometry. The peptides in the sample are ionized and energized by a laser-beam and are accelerated in
an electric field. The time of flight (=TOF) of each peptide fragment towards a target is measured. Since
the TOF is proportional to the mass/charge ratio of each peptide, the mass of the peptide can thus be
calculated. This way the mass spectra of the peptide fragments of a whole protein can be obtained. 
 
 
 
 
 
 
 
 
Fig. 2-4: Principle of MALDI-QTOF (quadrupole time-of-flight) tandem mass spectrometry. The sample is
ionized and energized by a laser-beam and flies into a quadrupole ion guiding cell (Q0), where the ions are
focussed and cooled. Then a peptide of interest (the parent ion) is selected at the quadrupole Q1-cell and
guided into the quadrupole collision cell (Q2). There the parent ion collides with argon atoms and splits into
daughter-ions. The masses of these daughter ions are then measured via TOF mass spectrometry. 
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 2.4.2 Peptide sequencing by MALDI-quadrupole time-of-flight tandem mass spec-
trometry 
 
The peptide mass data from MALDI-TOF mass spectrometry were used for database searches 
in order to identify the target protein by peptide mass fingerprinting. Sometimes no positive 
hit was found or the result did not satisfy the specified stringency criteria, which usually 
required more than four matched peptides at an accuracy of 0.1 Da. In this case, the peptide 
sequence of one or two abundant fragments was be determined directly by MALDI-QTOF 
tandem mass spectrometry. The full amino acid sequence of a peptide provides much more 
accurate information for further protein identification. It can also be used to confirm the 
results gained from peptide mass fingerprinting. MALDI-QTOF tandem mass spectrometry 
uses the MALDI ion source. The quadrupole filters peptides within a selected size range that 
are later guided into a collision cell to be broken into smaller fragments. The masses of these 
overlapping fragments are then analyzed by time-of-flight mass spectrometry (Fig. 2-4). 
Although this method is more complicated to perform, the results are more reliable than 
peptide mass fingerprinting because the sequence information of one or two peptides usually 
identifies the protein with high accuracy. Before the analysis with MALDI-QTOF mass 
spectrometry samples have to be purified by nano-scale reversed chromatography. This 
procedure removes salts and small chemical compounds of the buffer and thus reduces the 
chemical noise of the spectra and improves the sensitivity (Annan et al., 1996; Gobom et al., 
001). 
2.4.3 Database search based on peptide mass fingerprint spectra 
, ProFound, MS-Fit, PeptIdent, PeptideSearch, and PepSea (see “The 
st of internet sites”). 
 verification of the identity of a peptide. The search engine gives out a list 
f best matching proteins. 
e theoretical peptide mass 
ngerprint and the experimental one might be due to the following reasons:  
• 
ognize a certain cleavage 
site. This results in the increase of the number of missed cleavages.  
2
 
 
The obtained spectra of peptide masses are analyzed further by searching though different 
databases to find the corresponding protein. Each protein in the databases can be “digested in 
silico” by trypsin and thus provides a theoretical spectrum of its peptide masses. Comparing 
the experimental with the bioinformatic data, several candidate proteins with high probability 
scores can be identified. This task can be performed with the help of several search engines on 
the internet: MASCOT
li
 
Before the search, several parameters have to be set. These include the taxonomy of the 
specimen, the used protease and the number of accepted missed cleavages, the peptide mass 
states (usually the monoisotopic mass), the mass deviation tolerance, and possible 
modifications. Peptide modifications are important since they influence the peptide masses 
and might be introduced artificially in the preparation process (e.g. oxidation of methionine-
residues). The oxidation of an amino acid (e.g. methonine) in a polypeptide increases its mass 
by 18 Da. The number of 18 Da deviations should therefore correspond to the number of 
methionine residues in a certain peptide. On the other hand, this “artifact” may serve as a 
second independent
o
 
In general not all peptide masses in the spectra can be matched to the theoretical digestion of a 
protein. However, the larger the sequence to be covered by the fragments, the more 
statistically probable the result will be. Deviations between th
fi
 
Although several detergents like SDS have already denatured the proteins, any still 
existing secondary structures would hamper the enzyme to rec
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 • Any kind of modification would cause a deviation of peptide mass. More than 300 differ-
ent modification artifacts may be introduced during the whole procedure from protein ex-
traction to identification. The modification of cysteine by acrylamide and the oxidation of 
methionine are the most frequent modifications. Because of the high reactivity of the sulf-
hydryl group of cysteine, it would usually combine with the unpolymerized acrylamide 
during the 2D-electrophoresis. The oxidation of methionine results from its easily reduci-
ble sulfhydryl side chain.  
• The masses of the peptides are best calculated by using the monoisotopic peak of an 
internal calibration marker such as the auto-digestion product of bovine trypsin (residues 
50-69, M+H+ = 2163.06 Da) and the matrix trimer ion (3M+H+ = 568.14 Da). The read-
outs of the mass values are sensitively affected by the shape of the peak that depends on 
the mass/charge ratio (m/z) and the strength of the reflecting electric field. This electric 
field has a role to focus the molecules of the same mass in order to generate a slim peak. 
For larger peptides, however, the peak shape of the mass spectrum usually becomes 
broadened by unsatisfactory focussing. This might lead to false mass calculations. The use 
of sodium-containing buffers can also lead to broadened peak shapes since the molecule-
ion of (M+Na)+ instead of (M+H)+ can be detected wrongly. This would cause an increase 
of the m/z value.  
.  
• If two protein spots lie very close to or overlap each other in the 2D-electrophoresis gel, 
the overlay of two mass-spectra might disturb the correct identification of the single 
protein
 
Sometimes several less stringent criteria, such as more than one allowed missed cleavage, 
several kinds of possible modifications, larger mass deviation tolerances have to be granted in 
order to match the experimental peptide mass spectra to their theoretical ones. If this is not 
possible, it is advisable to sequence an abundant peptide in the spectrum by MALDI-QTOF 
tandem mass spectrometry. 
 
The following databases are used for confirmation of the protein matches: PeptideMass, 
BLAST2SEQUENCE, Swiss-Prot-TrEMBL, and NCBI (see “The list of internet sites”). 
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3 MATERIALS AND METHODS 
 
3.1 Preparation of lymphoblastoid cell pellets  
 
3.1.1 Chemicals and reagents 
 
Chemicals Company Ordering number 
RPMI 1640 (1*with L-glutamine) Biorad F1215 
fetal calf serum Gibco/BRL 10270-106 
streptomycin  Grünenthal 757753B 
penicillin Grünenthal E744114 
cyclosporine A, SandimmunR Sandoz PZN-2702663 
LiqueminR 25 000 U/ml Hoffmann-La Roche PZN-3441331 
FicollR separating solution 
(density 1.077 g/ml) 
Seromed L6115 
dimethylsulfoxide (DMSO) Merck 9678.0100 
colcemid  Gibco/BRL 15210-016 
 
3.1.2 Solutions  
 
RPMI 1640 500 ml 
fetal calf serum 50 ml 
streptomycin  50 mg 
culture medium 
penicillin 50,000 U 
filtered EBV-containing B95-8 supernatant 50 ml 
RPMI 1640 40 ml 
fetal calf serum 10 ml 
streptomycin 50 mg 
penicillin 50,000 U 
transformation medium 
cyclosporin A (SandimmunR) 100 µg 
hypotonic solution KCl 0.075 M 
culture medium 9 ml freezing medium 
DMSO 1 ml 
methanol 3 vol cold fixative 
acetic acid 1 vol 
 
3.1.3 Special equipment 
 
Equipment Company 
tissue culture flasks (50 ml) Nunc 
sterile filters Millex HA Millipore 
centrifuge with 3360/BS4402/A rotor Heraeus sepatech 
 
3.1.4 Procedure  
 
3.1.4.1 Preparation of transformation medium 
 
The protocol has been established by Neitzel (1986). Fig. 3-1 depicts the procedure. The Ep-
stein-Barr-Virus (EBV) for transformation is obtained from the lymphoblastoid marmoset 
19 
 (monkey) cell line B95-8 that is latently infected with EBV and can release virus particles into 
the culture medium. About 5 x 105 B95-8 cells/ml were suspended in culture medium and the 
EBV-containing supernatant medium was collected after 5 days of cultivation. Then the su-
pernatant was centrifuged at 400 g for 10 min to remove marmoset cells completely. After 
additionally being filtered twice through a 0.45 µm membrane filter, the supernatant was di-
luted 1:1 with fresh RPMI 1640, supplemented with 20% heat-inactivated fetal calf serum, 2 
mM L-glutamine, antibiotics and cyclosporin A, to obtain the virus pools, i.e. the transforma-
tion medium. 
 
3.1.4.2 Preparation of mononuclear leukocytes from whole blood 
 
The heparinated blood sample (500 IE Liquemin/ml blood) of a normal control patient was 
diluted 1:1 with RPMI 1640 and was overlaid on 5 ml Ficoll. The volume ratio of blood- 
 
 
 
 
 
 
 
 
e
e
a
R
4Fig. 3-1: Establishment of lymphoblastoid cell lines. The left column depicts the preparation of th
transformation medium. The right column depicts the preparation of the mononuclear cells. The final bottl
contains both the transformation medium and the mononuclear cells, which are set up for cultivation of 
lymphoblastoid cell line.  PMI mixture to Ficoll is 3-4:1. The step-gradient was centrifuged without brake at 400 g for 
0 min in a swinging bucket centrifuge. The ensuing ring of mononuclear cells at the interface 
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 between plasma and Ficoll was aspirated and washed/centrifuged (400 g, 10 min) three times 
with 10 ml RPMI. 
 
3.1.4.3 Establishment of the permanent cell culture 
 
The mononuclear leukocytes, including T- and B-lymphocytes were suspended in 
transformation medium. The pH of the cell culture was adjusted to 6.8 by overlaying it with 
CO2 and then the cells were incubated at 37°C in a 5% CO2 atmosphere. The medium was 
changed once a week by replacing half of the supernatant with a fresh medium containing 1 
µg/ml cyclosporin A. Cyclosporin A specifically inhibits the RNA polymerase of T 
lymphocytes thus removing the interfering T-lymphocytes.  
 
3.1.4.4 Preparation of the lymphoblastoid cell pellet 
 
The lymphoblastoid cell pellet was prepared after the cell line had been cultured for 3-4 
weeks. The total cell number was counted with a Neubauer’s chamber under a phase contrast 
microscope at 100 x magnification. The cultured cells were re-suspended by pipetting up and 
down and were transferred into centrifugation tubes. A pellet was obtained by centrifugation 
at 1050 g for 8 min.  
 
3.2 Preparation of mitochondria  
 
3.2.1 Chemicals and reagents  
 
Chemicals Company Ordering number 
sucrose Merck 7653.1000 
EDTA Merck 8418.0250 
3-morpholinopropanesulfonic acid (MOPS) Fluka 69948 
bovine serum albumin (BSA) Fluka 05488 
triethanolamine Fluka 90278 
digitonin Fluka 37006 
Percoll Fluka 77237 
Metrizamide Fluka 69753 
 
3.2.2 Solutions  
 
sucrose 100 mM 
EDTA 1 mM 
MOPS (pH 7.4) 20 mM 
medium A 
BSA 1 g/l 
medium A  
triethanolamine 10 mM 
Percoll 5% 
medium B (homogenization buffer) 
digitonin 0.1 mg/ml 
 
3.2.3 Special equipment  
 
Equipment Company 
motor driven tightly fitting Potter-Elvehjem homogenizer 
RZR 2051 (glass tube with Teflon pestle, diameter 6,8 mm) 
Heidolph  
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lumbar puncture syringe-needles (length: 7 cm, volume: 1 ml) Braun Melsungen AG 
ultracentrifuge with T1270 rotor (Sorvall ultra Pro 80) DuPont de Nemours 
GmbH  
 
3.2.4 Procedure 
 
The present protocol has been adapted and modified from Madden et al. (1987), Bourgeron et 
al. (1992) and Strack et al. (2001). Fig. 3-2 shows the procedure and the result of 
mitochondrial isolation. 
 
 
 
Fig. 3-2: Mitochondrial isolation by Percoll/metrizamide hybrid gradient
centrifugation. Electron microscopy reveals that the first fraction contains
mostly membrane debris from both cellular and subcellular organelles. The
material of the second fraction contains a few lysosomes and other
structures that are difficult to identify morphologically. Only the third
fraction contains highly enriched mitochondria. 
3.2.4.1 Preparation of the post-nuclear supernatant 
 
All procedures were carried out at 4°C to minimize protease activity. At first the cell pellet 
was washed and centrifuged (1050 g, 8 min) two times with medium A. Then it was 
resuspended with medium B and incubated for 5 minutes. Medium B contains digitonin that is 
incorporated into the cell membrane and thus makes the subsequent break-up of cells easier. 
The cells were disrupted with 5 up- and down-strokes of a Potter-Elevhjem-homogenizer at 
500 rpm. The homogenate was centrifuged at 1300 g for 5 min, and the supernatant was 
collected. The pellet was resuspended again in medium B and disrupted once more with the 
homogenizer. This step was repeated twice and the supernatants from each centrifugation-step 
were pooled as the “post-nuclear supernatant”. 
 
3.2.4.2 Preparation of a hybrid Percoll/Metrizamide discontinuous gradient 
 
A hybrid gradient was prepared from 35% Metrizamide (density 1.1304 g/ml), 17% Metri-
zamide (density 1.1029 g/ml), and 6% Percoll (density 1,0331 g/ml). All solutions were pre-
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 pared with 0.25 M sucrose and the concentrations were expressed as w/v. Gradients were 
poured into cellulose-nitrate ultracentrifugation-tubes. 1 ml of 35% Metrizamide was overlaid 
with 1 ml of 17% Metrizamide followed by 2.5 ml of 6% Percoll. The tubes were then gently 
filled with post-nuclear supernatant (about 3.7 ml) up to 4 mm below the upper rim. The solu-
tions were overlaid on top of one another with a long lumbar puncture syringe-needle. Cen-
trifugation was performed at 20,000 g without brake for 15 min at 4°C in an ultracentrifuge.  
 
3.2.4.3 Preparation of the mitochondrial pellet 
 
After centrifugation several distinct bands can be detected in the discontinuous hybrid 
Percoll/Metrizamide gradient. The band at the interface between 17% and 35% Metrizamide 
is highly enriched in mitochondria [Madden et al., 1987; Strack et al., 2001]. This band was 
aspirated with a Pasteur-pipette, diluted 1:4 with 0.25 M sucrose and centrifuged at 10,000 g 
for 10 min to wash away the remaining Metrizamide and to obtain a concentrated 
mitochondrial pellet at the floor of the centrifugation tube. An additional washing step could 
be added if necessary. 
 
3.3 Sample preparation of mitochondrial proteins  
 
3.3.1 Chemicals and reagents  
 
Chemicals Company Ordering number 
NaH2PO4*2H2O Merck 6580 
Na2HPO4 Merck 3090 
KCl Merck 4933 
MgSO4*7H2O Sigma M-1880 
urea Biorad 161-0730 
pepstatin A Sigma P-4265 
phenylmethylsulfonylfluoride Biorad 161-0202 
protease inhibitor mini (CompleteR) Roche 1.836.153 
glycerin Merck 4093 
3-[(3-cholamidopropyl)-dimethylammonio] 
-propan-sulfonate (CHAPS) 
Merck 1.11662.0001 
1,4-dithioerythritol (DTT) Biorad 161-0610 
ServalyteR pH 2-4 Serva 42902 
 
3.3.2 Solutions 
 
KCl 0.2 M 
glycerin 20% 
P2-CHAPS buffer 
phosphate buffer (0.2 M NaH2PO4 
and 0.2 M Na2HPO4, pH 7.2) 
0.1 M 
P2-CHAPS buffer  
MgSO4*7H2O 1 mM 
P2-CHAPS/MgSO4
CHAPS 0.14 M 
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pepstatin A 1.4 µM protease inhibitor (H1)  
(solved in ethanol) phenylmethylsulfonylfluoride 1.0 mM 
P2-CHAPS-Buffer 0.4 ml protease inhibitor 4 (H4) 
protease inhibitor mini (CompleteR) 1 tablet 
DTT solution DTT 21.6% 
 
3.3.3 Special equipment  
 
Equipment Company 
sonicator (Transsonic 310) Faust 
polished glass beads (diameter 2.5 mm) Carl Roth GmbH + Co Karlsruhe 
 
3.3.4 Procedure  
 
The protocol was performed according to Klose et al. (1999a). The mitochondrial pellet was 
weighed to calculate the required volume of each solution, including P2-CHAPS/MgSO4, 
protease inhibitor 1 (H1), protease inhibitor 4 (H4), and the required number of glass beads. 
The required volume of P2-CHAPS/MgSO4 was 1.25 times the weight of the mitochondrial 
pellet. 
ne 2.0-4.0. The homogenate was stored at –80°C before the 2D-electrophoresis was 
tarted. 
3.4 Bicinchoninic acid (BCA) protein assay 
3.4.1 Chemicals and reagents 
ny umber  
 
H1 protease inhibitor was calculated to be 0.02 fold and H4 protease inhibitor to be 0.08 fold 
of the combined masses of the mitochondrial pellet and P2-CHAPS/MgSO4. The number of 
the required glass-beads equaled to 0.034 x of the sum of the weight of mitochondrial pellet 
plus the volumes of all other solution components. The solutions were added directly onto the 
pellet. After adding the glass-beads to the homogenate, it was sonicated in an ice-cold water 
bath for 10 seconds followed by 40-45 seconds stirring and one minute keeping on ice. This 
sonication-round was repeated six times to guarantee that most of the mitochondrial proteins 
were solubilized. After 15 min stirring in a cold room, the required volume of benzonase was 
added to remove the mtDNA. The volume of the required benzonase equaled 0.025 x the 
weight of the homogenate after sonication. The homogenate was stirred for another 15 min at 
4°C before the protein-concentration was measured by the BCA protein-assay. This assay 
required about 1-5 µl homogenate. The rest of the homogenate was mixed with urea, DTT and 
ampholine pH 2.0-4.0 to yield final concentrations of 9 M urea, 70 mM DTT, and 2% 
ampholi
s
 
 
 
Chemical Compa Ordering n
BCA protein assay reagent (includes reagent A, 
agent B, and albumin standard) 
Pierce 23225BN 
re
 
3.4.2 Special equipment 
 
Equipment Company  
spectrophotometer (MRX) Dynal Biotech & Nordic  
microwell-plate NUNC TM Brand Products 
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 3.4.3 Procedure 
 
3.4.3.1 Preparation of diluted BSA serial standards  
 
The BSA standards were prepared by diluting a 2.0 mg/ml BSA stock standard serially with 
the same diluent as my sample. A list of standard dilutions with a working range from 20 
µg/ml to 2000 µg/ml is shown bellow: 
 
Volume of BSA  Volume of diluent  Final BSA concentration 
300 µl of Albumin Standard 0 µl  2000 µg /ml 
(A) 375 µl of albumin standard  125 µl  1500 µg /ml (A) 
(B) 325 µl of albumin standard  325 µl  1000 µg /ml (B) 
(C) 175 µl of (A) 175 µl 750 µg /ml (C) 
(D) 325 µl of (B) 325 µl 500 µg /ml (D) 
(E) 325 µl of (D) 325 µl 250 µg /ml (E) 
(F) 325 µl of (E) 325 µl 125 µg /ml (F) 
(G) 100 µl of (F) 400 µl 25 µg /ml (G) 
 
3.4.3.2 Protein quantification assay 
 
The BCA working reagent was prepared by mixing 50 parts of BCA protein assay reagent A 
(contains BCA) with one part of reagent B (contains CuSO4). Then 20 µl of each standard, the  
sample or diluent (as empty control) were pipetted into wells of a microwell-plate. 400 µl 
working reagent were added into each well sequentially. The plate was then covered and 
incubated at 37°C for 30 minutes in a water bath. After incubation, the plate was cooled to 
room temperature before final measurement. The protein concentration was measured 
colorimetrically at λ=570 nm with a spectrophotometer. The program “Revelation Version 
2.0” provided by the manufacturer was used for data processing. 
 
3.5 Two-dimensional protein electrophoresis 
 
3.5.1 Chemicals and reagents  
 
Chemicals Company Ordering number 
acrylamide Biorad 161-0100 
piperazine diacrylamide Biorad 161-0202 
TEMED Biorad 161-0800 
persulfate Biorad 161-0700 
urea (for gel solution) Biorad 161-0730 
urea (for electrode solutions) Merck 8484 
glycerin Merck 4093 
ethylenediamine Merck 800947 
85% phosphoric acid Merck 573 
Sephadex G-200R Pharmacia 17-0081-01 
Tris-base Sigma T-1503 
Tris-HCl Sigma T-3253 
sodium dodecyl sulfate (SDS) Merck 1.06498 
glycine Serva 23390 
PharmalyteR pH 3.5-10 Pharmacia 80-1125-87 
PharmalyteR pH 6.5-9.0 Pharmacia 17-454-01 
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PharmalyteR pH 4.0-6.5 Pharmacia 17-452-01 
PharmalyteR pH 5.0-8.0 Pharmacia 17-453-01 
SevalyteR pH 2.0-11 Serva 42-900 
AmberliteR IRN-150 Serva 1-0341 
ethanol Herbeta 21847 
methanol Baker 8045 
acetic acid Merck 8.00947 
 
3.5.2 Solutions 
 
Pharmalyte pH 3.5-10 12.5% (v/v) 
Sevalyte pH 2.0-11 12.5% (v/v) 
Pharmalyte pH 6.5-9.0 12.5% (v/v) 
Pharmalyte pH 4.0-6.5 37.5% (v/v) 
ampholine-mix 
Pharmalyte pH 5.0-8.0 25% (v/v) 
acrylamide 3.5% (w/v) 
piperazine diacrylamide 0.3% (w/v) 
urea 9 M 
TEMED 0.06% (v/v) 
glycerin 5% (w/v) 
ampholine-mix 4% (v/v) 
1D-separation gel 
persulfate 0.02% (w/v) 
urea 3 M 1D-anode solution  
 phosphoric acid 0.742 M 
urea 9 M 
glycerin 5% (w/v) 
1D-cathode solution 
ethylenediamine 0.749 M 
Sephadex G-200 12.5% (w/v) 
glycerin 12.5% (w/v) 
DTT 1.08% (w/v) 
ampholine-mix 2% (v/v) 
Sephadex mixture 
urea 9 M 
Tris-base 125 mM 
glycerin 40% (w/v) 
DTT 65 mM 
1D-incubation solution 
SDS 3% (w/v) 
acrylamide 15% (w/v) 
bisacrylamide 0.2% (w/v) 
Tris-base/Tris-HCl 0.375 M 
TEMED 0.03% (v/v) 
SDS 0.1% (w/v) 
2D-gel solution 
persulfate 0.08% (w/v) 
Tris-base 0.025 M 
glycine 0.192 M 
2D-electrode solution  
(both upper and lower) 
SDS 0.1 M 
ethanol  50% (v/v) 2D-fixation solution 
(silver stain) acetic acid  10% (v/v) 
methanol 50% (v/v) 2D-fixation solution 
(Coomassie stain) phosphoric acid 2% (v/v) 
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3.5.3 Special equipment 
 
Equipment Company  
apparatus for IEF and 40 cm glass tubes of two different  
diameters (0.9 mm and 1.5 mm) Fig. 3-3A 
self built 
apparatus for SDS-PAGE (Desaphor VA 300) Fig. 3-3B DESAGA 
circular cooling machine F25 Julabo 
PowerPac 3000 electrophoresis power supply Biorad 
1D-gel tube stand with special gel-solution groove self built 
polymerization stand Desaphor VA (2D polymerization stand) DESAGA 
1D-precision glass tubes 40 cm x 0.9 mm or 1.5 mm Schott 
pH-meter 766 with a micro electrode (type Inlab 422) pH-meter: Knick 
electrode: Roth 
 
 
         
 
 
 
Fig. 3-3B: equipment for SDS-PAGE. Fig.3-3A: equipment for isoelectric focussing. 
3.5.4 Procedure  
 
3.5.4.1 First dimension-isoelectric focussing (IEF) 
 
The isoelectric focussing is performed according to a protocol by Klose (1999b). In the first 
dimension two alternative gel containers were used. These are high precision capillary glass 
tubes with an internal diameter of 0.9 mm (thin) or 1.5 mm (thick) and a length of 400 mm. 
Gel solution was filled into the tubes by using accurately fitting nylon strings as plungers. 
After filling, the tubes were kept at room temperature to polymerize for 3-4 days before use. 
Before the protein samples were loaded onto the anodic end of the IEF-gel, a Sephadex mix-
ture – acting as a sieve – was loaded to a height of 2 mm. Gels were electrophoresed serially 
at 100 V for 1 hour, followed by 300 V for 1 hour, 1000 V for 23 hour, 1500 V for 30 min 
and finally at 2000 V for 10 min. After the IEF-run was finished, the gels were expelled di-
rectly into the 1D-incubation solution by a nylon string. They were incubated for 10 min at 
room temperature under continuous shaking and then placed completely relaxed onto the gel 
27 
 grooves and stored at –70°C until the second dimension separation of the 2D-electrophoresis 
was performed. 
 
3.5.4.2 Sodium dodecyl-sulfate polyacrylamide gel electrophoresis 
 
In the second dimension, 0.75 mm (thin) or 1.5 mm (thick) thick plastic spacers were used to 
fix the distance between the two glass plates of the electrophoretic cell. The first dimension 
(IEF) gel was gently transferred from the groove onto the surface of the SDS-PAGE gel with 
the help of a special wire-hook. Care was taken, not to stretch the gel. The IEF gel had to be 
in tight contact with the SDS-PAGE gel. The inclusion of air or solution between the gels had 
to be avoided. 1 % agarose solution was overlaid up to the edges of the glass cells to restrict 
the movement of the IEF gel. Gels were electrophoresed for the first 15 min at 65 mA (thin 
gel) or 130 mA (thick gel) and then at 75 mA (thin gel) or 150 mA (thick gel) for ca. 6-7 
hours. The temperature of the lower electrode solution was kept at 15°C by a spiral glass tube 
fixed to a circular cooling pump. Electrophoresis was finished when the bromophenol blue 
line in the gels reached a line that has been etched 2 cm from the lower edge of the frontal gel 
plate. After electrophoresis, the gels were transferred into 1 liter/gel 2D-fixation solution. 
After shaking for 2 hours, the gels were left standing overnight in the same solution at room 
temperature. 
 
3.5.4.3 Measurement of the pH-gradient of the IEF-gel 
 
The isoelectric focussing of two Ø 1.5 mm tube gels was performed as described above. One 
of the gels was loaded with 10 µl of mitochondrial protein sample, the other was left empty as 
a control. After the isoelectric focussing was finished, the gels were expelled and cut into 5 
mm sections which were put directly into individual Eppendorf test tubes with 40 µl degassed 
aqua bidest. The Eppendorf tubes were closed in a nitrogen atmosphere. The gel sections were 
sonicated in an ice-cold water bath for 15 min in order to release the ampholytes from the gel 
into the water. The pH-measurement was carried out with a microelectrode. The pH of each 
gel-section was measured for 2 min until stable readings were obtained.  
 
3.6 Gel staining and drying  
 
3.6.1 Chemicals and reagents 
 
Chemicals Company Ordering number 
sodium acetate ICN 195496 
sodium thiosulfate ICN 191447 
glutardialdehyde Merck 8.20603 
ethanol Herbeta 21847 
sodium carbonate Merck 1.06392.0500 
silver nitrate ICN 195495 
formaldehyde ICN 194047 
EDTA Merck 1.08418.0250 
thimerosal ICN 103044 
ammonium sulfate Sigma A-9141 
Serva Blue G-250 R Serva 35050 
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 3.6.2 Solutions 
 
sodium acetate 0.5 M 
sodium thiosulfate 0.2% (w/v) 
glutardialdehyde 0.5% (v/v) 
S-incubation solution 
ethanol 30% (v/v) 
silver nitrate 0.1% (w/v) S-stain solution 
formaldehyde 0,01% (v/v) 
S-wash solution sodium carbonate 2.5% (w/v) 
sodium carbonate 2.5% (w/v) S-developer solution 
formaldehyde 0.01% (v/v) 
EDTA 0.05 M S-stop solution 
thimerosal 0.02% (w/v) 
methanol 34% (v/v) 
phosphoric acid 2% (v/v) 
C-incubation solution 
ammonium sulfate 17% (w/v) 
methanol 34% (v/v) 
phosphoric acid 2% (v/v) 
ammonium sulfate 17% (w/v) 
C-stain solution 
Serva Blue G-250 0.066% (w/v) 
C-wash solution methanol 25% (v/v) 
 
3.6.3 Special equipment and material 
 
Equipment  Company  
shaker (3016) Gesellschaft für Labor mbH 
plastic troughs (bottom 30*40 cm) Brukle-Labo-Plast 
drying/vacuum incubator (type UL-60) Memmert 
water-saving vacuum pump (type TOM JET 1/A4) Genser Wissenschaftliche Apparate 
water-jet vacuum pump  Th. Geyer 
cellophane  Gehring & Neidweiser GmbH & Co  
 
3.6.4 Procedure  
 
3.6.4.1 Silver staining 
 
The silver staining was performed according to a protocol by Klose (1999b). Silver staining is 
a very sensitive method with a detection limit between 1-10 ng. It is based on the high 
reducibility of silver ions. The silver ions form complexes with proteins much stronger than 
with the polyacrylamide gel. Complexed silver ions can be reduced much faster than free 
silver ions. During the whole procedure of silver staining, the gels were shaken continuously. 
After each step, the solutions were removed by suction of a water-jet pump. The gels were at 
first incubated in S-incubation solution for 2 hours. During this period, the sodium thiosulfate 
and glutardialdehyde in the solution act as complexing agents and link the proteins by 
forming covalent bonds. After that, two rinsing steps with distilled water were performed for 
20 min. This had to be done to minimize background staining by washing away the unbound 
glutaraldehyde. The silver staining lasted for 30 min. In this step formaldehyde was used as 
reducing agent. After that, the gels were washed in S-wash solution for 1 min and developed 
by S-developer solution for several minutes and then finally stopped by S-stop solution. 
 
29 
 3.6.4.2 Colloidal Coomassie staining 
 
The colloidal Coomassie staining was performed according to a protocol by Klose (1999b). 
Coomassie staining is a method that visualizes proteins due to the unspecific binding of the 
dye to their amino acid residues. The detection limit is around 1 µg. Compared to the standard 
Coomassie staining method, the colloidal Coomassie staining is more specific and sensitive, 
since the colloidal Coomassie dye is much finer than the standard Coomassie dye. The 
colloidal Coomassie dye penetrates better through the polyacrylamide gel and thus binds to 
the proteins more easily. The whole procedure of colloidal Coomassie staining was carried 
out under continuous shaking. After overnight fixation in C-solution, the gels were at first 
washed three times with distilled water for 30 min. Then they were incubated in C-incubation 
solution for 1 hour followed by 5 days staining with Coomassie brilliant blue G-250. The 
destaining step with C-wash solution lasted 1-2 hours by using a piece of sponge which acts 
as adsorbent for the washed out dye. The whole procedure was stopped when the protein spots 
stood out clearly from the background. One should not destain the gels for too long since the 
color of the protein spots also faded with time. 
 
3.6.4.3 Gel drying and preserving 
 
After staining the results had to be stored and the gels had to be preserved. Still wet, the gels 
were scanned on a transilluminating scanner and stored as TIFF-files with a resolution of 150-
300 dpi. Later the gels were dried to preserve them for the records. They were “sandwiched” 
between two sheets of wet cellophane and thick filter papers and were put on a drying panel. 
Excess water as well as air bubbles between the layers of filter paper, cellophane, and the gel 
were expelled with a ruler. The gels were then dried in a heated vacuum incubator for 
approximately 2-3 hours at 80°C. The dried gels were labeled with the sample name and the 
date and stored in large envelopes tagged with all the information of the 2D-electrophoresis 
runs. 
 
3.7 Sample preparation for MALDI-TOF protein mass fingerprinting 
 
3.7.1 Chemicals and reagents 
 
Chemicals Company  Ordering number
trypsin Roche 1047841 
ammonium bicarbonate (NH4HCO3) Sigma A-6141 
acetonitrile Baker 9017-54 
formic acid Sigma F-0507 
α-cyano-4-hydroxy cinnamic acid Sigma C2020 
trifluoroacetic acid (TFA) Merck 8178.0050 
 
3.7.2 Solutions 
 
100 mM NH4HCO3 60% (v/v) destaining solution 
acetonitrile 40% (v/v) 
trypsin 10 ng/µl trypsin solution 
NH4HCO3 50 mM 
formic acid solution formic acid 5% (v/v) 
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α-cyano-4-hydroxy 
cinnamic acid 
15 mg/ml 
0.1% (v/v) TFA 30% (v/v) 
matrix 
 
acetonitrile 70 % (v/v) 
 
3.7.3 Special equipment 
 
Equipment Company 
skin-biopsy punch (various diameters) Stiefel 
vacuum centrifuge (Speedvac) (PLCT 60-E) Heraeus 
incubator (PersonalHyb) Stratagene 
shaker (AVM) ETS Jean Robin 
 
3.7.4 Procedure 
 
3.7.4.1 In-gel digestion 
 
Protein spots were excised from the gel with a skin-biopsy punch and placed into the 
destaining solution. After shaking overnight at room temperature, they were dehydrated by 
addition of 100 µl acetonitrile. The liquid phase was removed, and the gel pieces were 
completely dried in a vacuum centrifuge. The gel pieces were then re-hydrated in the trypsin 
solution at 4°C for 45 min to let the trypsin permeate into the gel pieces without self-
digestion. The digestion was allowed to proceed overnight at 37°C by keeping the gel pieces 
wet. Peptides were extracted by letting the gel-piece swell three times with 5% formic acid 
and shrink four times with acetonitrile. The whole liquid phase was collected and finally dried 
down in a vacuum centrifuge. 
 
3.7.4.2 Sample preparation for MALDI analysis 
 
The peptide-samples were solved in 10 µl 0.1% TFA. 1 µl of the sample was spotted onto the 
MALDI target plate and mixed with 1 µl of 2% TFA and 1 µl matrix. After the sample spots 
had air-dried completely, they were rinsed twice with 5-10 µl 0.1% TFA, and the remaining 
liquid was evaporated with pressurised air. 
  
3.8 Peptide mass fingerprinting by MALDI-TOF mass spectrometry 
 
3.8.1 Special equipment 
 
MALDI-TOF mass spectrometer (Reflex II from Bruker-Daltonik, Bremen) 
 
3.8.2 Procedure 
 
Mass spectra of the peptide mixture were obtained using the Bruker Reflex II mass spec-
trometer operated in the reflector mode. The instrument is fuctions in the “delayed extraction” 
mode that ensures a mass resolution up to at least 6000 Da over the entire mass range and a 
mass accuracy of better than 0.1 Da with internal calibration. A total of 100-140 single-shot 
spectra were accumulated from each sample. They were calibrated using the monoisotopic 
peak from a known auto-digestion product of bovine trypsin (residues 50-69, M+H+ = 
2163.06 Da) and the matrix trimer ion (3M+H+ = 568.14 Da) as internal standards. The 
XMASS 5.0 software packages provided by the manufacturer were used for data processing.  
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3.9 Computer aided analysis of protein mass fingerprints 
 
The identification of proteins by their peptide mass fingerprints was mainly performed with 
the Mascot Software (Matrix Science Ltd.) and additionally with ProFound or PeptideSearch 
as search engines. The parameters were choosen as shown in Fig. 3-4. 
 
 
 
 
 
 Fig. 3-4A: the first step of
database search for
proteins. Example of the
parameters used for the
database search with the
Mascot search engine. The
parameters such as taxo-
nomy, allowed missed
cleavages, variable
modifications, and peptide
mass tolerance were
restricted as shown. Only
the monoisotopic peptide
masses were considered in
this search.  Fig. 3-4B: the second step 
of database search for 
proteins. The first protein 
is usually the best fit. The 
full name of the candidate 
protein together with its 
gi-number, the theoretical 
molecular weight, the 
probability based Mowse-
score and the number of 
matched peptides are all 
listed. Normally, there are 
several peptides or 
proteins listed in one 
suggestion. They generally 
are various fragments of 
the same protein.  
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Fig. 3-4C: The third step of
the database search. The
detailed view of a certain
protein, e.g. the ATP
synthase beta-chain,
includes information on the
protein and on the sequence
of the protein covered by
the peptide mass fingerprint
(highlighted in red). The
full information of the
protein can be accessed
from the NCBI database, by
clicking on the accession
number (gi number) of the
protein. 
After a protein had been found, the fingerprint data were compared with the theoretical 
digestion product of the protein. If no clear relation of the molecular weights between the 
“experimental” and the “theoretical” fragments could be found, I tried to use several less 
stringent criteria to improve the matching rates. This was expecially the case for large peptide 
fragments with molecular weights above 2,000 Da. The less stringent criteria comprised the 
allowance of up to four missed cleavages, the modification of cysteine by acrylamide and a 
larger tolerance of mass deviation of ± 0.5 Da.  
 
3.10 Peptide sequencing by MALDI-QTOF mass spectrometry 
 
3.10.1 Chemicals and reagents 
 
Chemicals Company  Ordering number
acetonitrile(HPLC-grade)  Baker 9017-54 
2,5-dihydroxybenzoic acid Sigma G-5254 
isopropanol Merck 1.09634.1000 
POROS 10 R2 reversed-phase chromatography 
medium R
PerSeptive 
Biosystems 
1-1118-02 
 
3.10.2 Solutions 
 
2,5-dihydroxybenzoic acid 5 mg/ml 
acetonitrile 3 vol 
matrix 
0.1% (v/v) TFA 7 vol 
POROS 10 R2; reversed-phase 
chromatography medium  
solution 
POROS 10 R2 reversed-phase  
chromato-graphy medium saturated  
with isopropanol 
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3.10.3 Special equipment 
 
Equipment  Company  
GELoader pipette tip Eppendorf 
plastic syringe (1.25 ml) Eppendorf  
API QSTAR Pulsar I mass spectrometer 
equipped with a MALDI ion source 
Applied Biosystems/MDS Sciex 
 
3.10.4 Procedure 
 
3.10.4.1 Sample purification by nano-scale reversed-phase chromatography 
 
Sample purification was performed according to a protocol by Gobom (2001). A long, narrow 
pipette tip packed with 0.3 ml POROS 10 R2 reversed-phase medium served as a chromato-
graphy column. All the sample liquid was driven through the column by a disposable plastic 
syringe. Prior to use, the column was washed with 15 µl of acetonitrile-0.1 % TFA (8:2 v/v) 
followed by an equilibration step with 10 µl of 0.1% (v/v) TFA. The peptide sample was 
acidified with 2 µl 2% (v/v) TFA to obtain a final concentration of about 0.2-0.5 % (v/v). 
Then the sample was loaded onto the column and was slowly pumped over the reversed-phase 
medium. A washing step was performed with 10 µl 0.1% TFA, and the column was emptied 
completely by pressing air through it for a few seconds. Finally, 3 µl matrix as an eluent were 
loaded on the column and the eluate was loaded directly onto the target of the MALDI-QTOF 
mass spectrometer. 
 
3.10.4.2 Protein ladder sequencing of peptide fragments 
 
These experiments were performed within the selection cell (Q1) and the collision cell (Q2). 
All ions were transmitted resulting in the measurement of the entire mass range. The ion of 
interest was selected at first in cell Q1, then this precursor ion was split in the collision cell Q2 
using argon as a collision gas. The ensuing fragments were analyzed in the TOF section of the 
instrument. The instrument was calibrated externally with peptides of known masses. The 
data processing was done with the “ANALYST” software packages provided by the 
manufacturer.  
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4  RESULTS 
 
The aim of this study was to establish a reference 2D-electrophoresis map of human 
mitochondrial proteins. Since this basic work should find its application in future diagnostic 
tests for patients with mitochondriopathies, I chose a material that can easily be obtained from 
patients. Immortalized cultured lymphoblastoid cells are easy to handle, can grow in non-
adherent cell-cultures and were therefore the material of choice. The combined methods of 
2D-electrophoresis and mass spectrometry were used to separate and to identify the proteins. 
All procedures and their respective results are summarized in Fig. 4-1. The whole project 
started with the establishment of an immortalized lymphoblastoid cell line. The electron 
microscopic photographs from the cells show that each lymphoblastoid cell contains about 
15-20 mitochondria (Fig. 4-2). The mitochondria were isolated and enriched by 
homogenization followed by density gradient centrifugation. All three ensuing fractions were 
examined by electron microscopy (Fig. 3-2). Only the third fraction, which contained the 
mitochondria, was used in subsequent experiments. The mitochondrial proteins were 
separated by 2D-electrophoresis and stained with Coomassie brilliant blue. The protein 
identification was performed with MALDI-TOF mass spectrometry and subsequent database 
searching. The identified proteins were marked on the 2D-electrophoresis map to get the final 
ference map. re
 
 
4.1 Mitochondrial isolation 
tinuous gradient. Floating material could be found between the surface of the gradient and the 
astoiFig. 4-2: Electron microscopic picture of a lymphobl d 
cell. Each cell contains a t 15-20 mitochondria. bou
 
 
In order to study the mitochondrial proteome specifically, I chose as raw material the mito-
chondrial fraction instead of whole lymphocyte preparations. In Fig. 4-3 the 2D-
electrophoresis gels of the lymphocyte proteome (A) and the mitochondrial proteome (B) are 
compared to each other. On the mitochondrial gel there are much less spots than on the whole 
lymphocytes’ gel. Some spots, which are fairly weak or even barely visible on the lympho-
cytes’ gel, show up intensely on the mitochondrial gel (highlighted with red arrows in the 
mitochondrial gel). For isolation of mitochondria from lymphoblastoid cells the first aim was 
to gain enough mitochondria from as little material as possible. The second aim was to mod-
ify the current protocols of mitochondrial isolation to increase the purity of the mitochondrial 
fractions. In my experiments a total of 108 cells was sufficient to obtain enough purified mito-
chondria from one patient to be able to perform two large gel 2D-electrophoresis runs, i.e. 
about 108 cells yielded 12-20 mg mitochondria. At the mitochondrial isolation procedure (see 
chapter 3.2.4), after ultracentrifugation I detected three distinct fractions in the hybrid discon-
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Fig. 4-1: This summary describes the procedures and the results of this study step by step. The work
started from the establishment of a lymphoblastoid cell line. The electron microscopic photographs
showed that each lymphocyte contains about 15-20 mitochondria. The mitochondria were isolated after 
homogenisation of the lymphocytes followed by density gradient centrifugation. The three fractions were
examined by electron microscopy. Only the third fraction was enriched of mitochondria. This fraction was 
used in subsequent experiments. The mitochondrial proteins were separated by 2D-electrophoresis and 
stained with Coomassie brilliant blue. The various protein-spots were cut out and were digested with 
trypsin. A peptide mass fingerprint or a peptide ladder were then generated with MALDI-TOF or MALDI-
QTOF respectively. After database searching, the identified proteins were marked on the 2D-
electrophoresis gel in order to obtain the final reference map. 
interface between sample and 6% Percoll; a second ring was seen at the interface between 6% 
Percoll and 17% Metrizamide; and a third fraction lay at the interface between 17 % and 35 %  
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Fig. 4-3: Comparison of the 2D-electrophoresis maps of lymphoblastoid cells and of isolated mitochondria.
Sub-cellular fractionation can intensify low abundant proteins and let them become visible. (A) depicts the
map of lymphoblastoid cells, (B) depicts the map of the mitochondrial subfaction. The red arrows point to
some intensified protein spots on the mitochondrial map. The green arrows point to the corresponding spots
in the lymphoblastoid map. 
 
 
 
 
 
Metrizamide. I investigated the pellet of each of the three fractions by electron microscopy 
(Fig. 3-2). The material of the first fraction contained mainly membranes from both cell and 
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 subcellular organelles. In the second fraction I found a few lysosomes and some other mate-
rial which was difficult to identify. Only the third fraction was highly enriched in mitochon-
dria. I only used the pellet from the third fraction. The high purity of the mitochondrial frac-
tion was confirmed by the subsequent experiments. Protein analysis by MALDI-TOF mass 
spectrometry identified only few non-mitochondrial proteins. 
  
4.2 Preparation of protein samples 
 
The protein samples of the mitochondria were prepared according to a protocol by Klose 
(1999a) (see chapter 3.3). The sample was treated with high concentrations of urea and with a 
detergent (CHAPS) to solubilize the membrane proteins. The protein concentration of the 
final sample was measured by using the BCA protein assay method (see chapter 3.4). Fig. 4-4 
gives an example of the result of the protein concentration measurement. The concentration of 
the protein samples of each experiment was around 8-10 mg/ml.  
 
 
4.3 2D-electrophoresis of mitochondrial proteins  
 
4.3.1 The pH-gradient of the IEF-gel 
 
The pH-gradient of the IEF-gel was measured as described abo
results are shown in Fig. 4-5A. The measured spots tend to lie on a
[pH]= -0.1088x [length of the gel] + 8.8965, starting from the basic
R2=0.939 (p<0.0001)). The gradient is linear between the pH-value
protein sample on the pH-gradient was also investigated (Fig. 4-5B
pH-gradient of the protein containing gel fluctuated more than that o
regression lines were nearly similar (y = -0.098x + 8.85, R2
regression lines, the best fit and the variance were caluclated w
package “StatView version 4.5.” 
 
4.3.2 Two-dimensional electrophoresis  
 
A total of about 500 µg protein sample was loaded on the anodic en
sing gel for a thick (1.5 mm) Coomassie stained large gel. In cont
protein sample was required for a thin (0.9 mm) silver stained geFig. 4-4: Analysis of the
protein concentration with
the BCA protein assay. The
result has to be multiplied
by ten (highlighted with
red), since the sample had
been diluted 10 times
before the measurement.  
 
ve (Section 3.5.4.3). The 
 straight regression line (y 
 end, with a dispersion of 
s of 5-9. The effect of the 
). Despite the fact that the 
f the empty gel, the linear 
=0.922 (p<0.0001)). The 
ith the statistic software 
d of the isoelectric focus-
rast, only one tenth of the 
l. A broad pH-range am-
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 pholine mixture of pH 2-11 was used for isoelectric focussing in order to get a “panorama 
view” of the mitochondrial proteins. The isoelectric point of the most acidic spot detectable 
was at pH 5.00 and that of the most basic one at pH 9.75. 
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sFig. 4-5A-B: pH-gradient of 40 cm IEF gels. The pH-measurement was performed as described in section
3.5.4.3. The results of the empty control gel are depicted in (A). The measured spots tend to lie on a
regression line (y = -0.1088x+8.8965, R2= 0.939 (p<0.0001)). The gradient is linear between the pH-values
of 5-9. The effect of the protein sample on the pH-gradient is shown in (B). Although the pH-gradient of
the protein containing gel fluctuated more than that of the empty gel, the linear regression lines are similar
(y= -0.098x+8.85, R2= 0.922 (p<0.0001)).he second dimension gel (SDS-PAGE) was run with a molecular weight standard. The 
olecular weight range of the standard marker lay between 17.5 and 76 kDa. The 
eproducibility of the 2D-electrophoresis runs was demonstrated by analyzing an identical 
ample on four different gels. Most spots were reproduced on each gel except in the case if 
he extreme ends of the first dimension gels were accidentally lost in the process of expulsion 
rom the glass tube. In Fig. 4-6 a comparison of the same region of the four different gels is 
hown. 
.3.3 Gel staining 
ontrast to the spots from the Coomassie gels I could not identify a single 
pot from the silver stained gel. 
he difference between silver stain and Coomassie stain is that the silver stain is more 
ensitive but the Coomassie stain has less influence on the proteins. The silver stained gel 
ay show more spots, but for the purpose of protein identification, the Coomassie stain is 
ore favorite since it does not modify the proteins covalently. The silver stain requires only 
ne tenth the amount of protein sample compared to the Coomassie stain. Fig. 4-7 shows the 
omparison of two gels stained by these two methods. A total of 420 spots could be separated 
nd detected on a silver stained gel from only 50 µg protein sample. In comparison, less than 
0 spots were detected on the same gel stained with Coomassie. However, the subsequent 
rotein analysis by MALDI-TOF mass spectrometry showed the drawback of the silver stain. 
or protein identification a total of 184 spots were excised from two gels stained with 
olloidal Coomassie brilliant blue. I could identify 115 spots by peptide mass fingerprinting 
ia MALDI-TOF mass spectrometry. The rest of the Coomassie gel was then destained and 
ubsequently restained with silver. The spots now appeared to be much darker than in the 
receding Coomassie stain. Additional 300 spots that had not been excised before from the 
oomassie-gels were cut out. After reduction of the silver with iodine salt and DTT and 
ubsequent trypsin digestion these spots were also subjected to MALDI-TOF mass 
pectrometry. In c
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Fig.4-6: These four corresponding gel-sections demonstrate the reproducibility of 2D-electrophoresis.
All four gels were stained with silver.  
Fig. 4-7: These two gel-sections demonstrate the difference in sensitivity between the silver (A) and the
Coomassie G-250-stain (B). Both gels have been run under the same conditions. A total of 525 µg
mitochondrial protein were loaded on gel B. In contrast, only 47 µg protein were loaded on gel A.
Moreover, it achieved a higher resolution than gel B. 40 
 4.3.4 Influence of repeated freezing-thawing cycle on sample quanlity 
 
In order to test the influence of repeated freeze-thaw cycles on sample quality, the same 
sample was run after the first thawing (gel A) and additionaly after refreezing and rethawing 
(gel B). Although the amount of sample loaded on gel B was 2 µl more than that of gel A 
many spots on gel B are much fainter than the corresponding ones on gel A. This experiment 
demonstrates the loss of proteins during the procedure of repeated freeze-thaw cycles.  
 
 
 
 
Fig. 4-8: The effect of repeated
freeze-thaw cycles on sample
quality: Comparison of the two
gels that have been prepared from
frozen stocks. Gel A used the
sample that was run on the 2D-gel
after the first time thawing. Gel B
used the sample that was run on
the 2D-gel after an additional
round of freezing and thawing.
Although the amount of loaded
sample of gel B was 2 µl more
than that of gel A, many spots on
gel B are much fainter than the
corresponding ones on gel A.  
 
4.4 Protein identification 
 
4.4.1 MALDI-TOF and MALDI-QTOF tandem mass spectrometry 
 
The proteins were identified by MALDI-TOF mass spectrometry on the basis of their peptide 
mass fingerprints, and by MALDI-QTOF tandem mass spectrometry on the basis of their 
peptide fragment ladders. A total of 184 spots was excised from two large Coomassie-stained 
2D-electrophoresis gels. Following in-gel digestion with trypsin, the peptide mixture of each 
protein was analyzed by MALDI-TOF mass spectrometry (see sections 3.7-3.10). 
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 Fig. 4-9: The mass spectrum of spot 3. A total of 60 peptides were detected by MALDI-TOF analysis. 
Using the Mascot search engine, 28 peptides labelled with a green dot (   ) could be matched to the
theoretical trypsin digest of the protein (ATP-synthese beta-chain, mitochondrial precursor). The 
parameters for this search were one missed cleavage, possible methionine oxidation and 0.1 Da mass
tolerance. All methionine containing peptides and their oxidized derivatives are grouped with the red M 
(M). The presence of double-peaks separated by 16 Da confirms the presence of methionine residues in the
respective peptide fragment. One fragment resulting form trypsin self-digestion is marked with pink color 
(trypsin). When less stringent criteria were used, some more peptides could be matched. If the mass
tolerance is increased to 0.5 Da, additional fragments can be matched (    ). If the number of possible
missed cleavages is increased to four, an additional large fragment can be matched (    ). 
 
heoretically, all the measured peptide masses should match the corresponding “in silico” 
igested fragments of a certain protein in the database. However, in the experimental setting 
e highest percentage of matched peptide masses in my study was 76%. The average 
ercentage of matched peptide masses was 44% and that of the covered sequence was 33%. In 
rder to confirm these primary results, verification of each spot was carried out “by hand”. 
ig. 4-9 shows an example using the mass spectrum information of spot 3. Each measured 
eptide mass was compared to the “in silico” digested ones. The matched peptides were 
ighlighted and marked with a green dot. The methionine containing peptides and their 
orresponding oxidized derivatives (oxidation of every methionine leads to a mass increase of 
6 Da), which strongly confirmed the identity of the peptide, were marked as a group. The 
eptide masses of the self-digested trypsin fragments were marked as well. Sometimes, in 
rder to match more peptides, less stringent criteria were used. These peptides (e.g. with one 
r two missed cleavages) were also highlighted. If the mass spectrum was not good enough to 
cure a protein identity, the amino acid sequence of a single fragment was determined by 
ALDI-QTOF tandem mass spectrometry. The sequence information could then be used as 
quence tag to find the protein in the database.  
42 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4-10A: The mass spectrum of spot 30 measured with MALDI-TOF mass spectrometry. Only 6 
peptides were detected including 3 peptides of the self-digested trypsin.  
Fig. 4-10B: The mass spectrum of spot 30 after desalting with nano-scale reversed-phase chromatography.
A total of 22 peptides was now detected by MALDI-TOF mass spectrometry. One isolated peptide was
selected out for further MALDI-QTOF measurement (highlighted with a red arrow). Peptide ladder
sequencing had to be performed because this spectrum was still not good enough to identify the protein.  
 
In Fig. 4-10A-D an example of this “manual” process is shown using the mass spectrum 
information of spot 30. The mass spectrum of spot 30 was not satisfactory when analyzed by 
MALDI-TOF mass spectrometry. Only six peptides were detected including three peptides 
generated by trypsin self-digestion. Sometimes salts from the buffer interfere with the 
MALDI-TOF mass spectrum. Therefore the peptides were first desalted by reversed-phase 
chromatography (see section 2.4.2). After desalting, a total of 22 peptides of spot 30 could 
then be detected with MALDI-TOF mass spectrometry. However, since the spectrum 
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Fig. 4-10C: The mass spectrum of the 1168.67 Da peptide of spot 30 using MALDI-QTOF tandem mass
spectrometry. These fragments are used to generate the protein sequence tag by GPMAW32-software on
the internet (see following figure).  
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 Fig. 4-10D: The sequence result of the isolated 1168.67 Da peptide of spot 30. The peptide fragment 
ladders were obtained by the MALDI-QTOF mass spectrometry. This sequence tag was later used for
database searching in order to identify the protein.f 22 peptide fragments was still not good enough to identify the protein, MALDI-QTOF 
nalysis had to be carried out on one isolated peptide. The sequence result of the isolated 
olypeptide of spot 30 led to the identification of the 13 kDa subunit of complex-I. I identified 
 total of 115 protein spots that corresponded to 95 different proteins. Most of them were 
entified by MALDI-TOF mass spectrometry, only five spots needed to be analyzed with 
ALDI-QTOF tandem mass spectrometry. In Fig. 4-11 the strategy of protein identification 
 illustrated. 
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Fig. 4-11: Strategy of protein identification. 
 
 
4.4.2 Database search for protein identification 
 
I used several search engines on the internet including Mascot, ProFound, and MS-Fit. These 
programs match the peptide masses from a protein spot with the “in silico” digested peptide 
masses of all known human proteins in the National Centre for Biotechnology Information 
non-redundant (NCBInr) protein database. At least five or more matching peptides were re-
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 quired for a secure identity assignment. With the Mascot search engine, most samples could 
be identified satisfactorily with a significant probability score (p<0.05). However, several 
spectra had to be handled with other search engines like ProFound and MS-Fit. A total of 
eight spots could be identified additionally that way. As mentioned above there were still five 
spots that could only be identified by their peptide sequence information gained from 
MALDI-QTOF tandem mass spectrometry. Finally I identifie 115 spots, which are listed in 
Tab. 7-1. The theoretical and the experimental molecular weights (MW) and isoelectric points 
(pI) of the identified proteins, their corresponding SWISS-PROT accession numbers are also 
listed, along with the data from the mass spectrometric analysis; i.e. the numbers of matching 
peptides, the sequence coverage (in percent) and the probability of assignment of a random 
identity. 
 
4.5 Mitochondrial proteome reference map 
 
4.5.1 Mitochondrial proteome reference map 
 
Fig. 4-12 shows a representative mitochondrial proteome map from human lymphoblastoid 
cells. All of the identified spots are highlighted in red with the corresponding spot number 
near them. The pI and MW are shown as well. The detailed information of the proteins is 
listed in Tab. 7-1 and also labelled directly in the 12 sectors of the reference map (see 
supplementary meterial: Fig. 4-12#1 to 4-12#12). A total of 184 spots from two Coomassie 
stained gels (corresponding to 141 different spots) resulted in the identification of 115 spots 
(corresponding to 95 different proteins). Out of the 400 visible protein spots on the silver gel I 
thus could identify 20%. Among the 95 identifed proteins, 77% (n=74) were annotated 
according to NCBI and SWISS-PROT databases, as mitochondrial proteins. Although our 
mitochondrial fraction was highly purified, it still contained some proteins from other 
subcellular organelles. In our sample, 15 spots corresponding to 11 different gene-products 
belong to subcellular components other than the mitochondria. The location of them is 
indicated below. There are ten proteins remaining whose functions and/or localization are 
unknown. For four of them (spots 46, 73, 129, 131) were only found as ESTs in the databases. 
All of the identified spots are grouped in Tab. 4-1 according to their location and function. 
The 25 spots that did not give a result on MALDI-TOF mass spectrometry were very weak 
spots that contained too little protein to produce a satisfactory spectrum.  
 
4.5.2 Locations of the identified proteins  
 
Based on the annotation in the NCBI and SWISS-PROT databases, a total of 74 identified 
proteins out of 90 spots were annotated as “mitochondria-associated” proteins. 27 of these 
proteins are located in the mitochondrial matrix, 16 in the mitochondrial inner membrane, 2 in 
the mitochondrial outer membrane, and 2 in the mitochondrial inter-membrane space. The 
remaining 27 proteins are surely mitochondrial proteins, however, their exact subcellular 
location is not clear. A total of eleven proteins out of 15 spots are located elsewhere. Seven of 
them are located in the cytoplasm, three at the endoplasmic reticulum, and one is known as B-
cell-associated protein. The subcellular location of ten proteins is unknown. These data are 
listed in detail in Fig. 4-13 and in Tab. 4-2. 
 
4.5.3 Functions of the identified mitochondrial proteins 
 
According to the annotation in SWISS-PROT and to the classification system of MITOP, I 
sorted the identified mitochondrial proteins. The sorting is based on the protein function and 
is summarized in Tab. 4-1. Most of these proteins (59 proteins) are part of central metabolic 
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 pathways, including the citric acid cycle, the pyruvate dehydrogenase complex, the respira-
tory chain, the β-oxidation, protein assembly or catabolism (urea cycle). Another group of 
proteins are transport proteins (seven proteins). Proteins that have a role in cell protection or 
apoptosis or heme- biosynthesis or cell maintenance, are grouped in “other functions” (eight 
proteins). The function of only one protein, the ES1 protein homologue mitochondrial percur-
sor, is not yet characterized. However, this protein is assumed to play an important role, since 
a homologous protein has been identified in the zebra fish (Danio rerio) and in Escherichia 
coli. One of the most important functions of the mitochondrion is the oxidative phosphoryla-
tion at the respiratory chain. 16 of the identified proteins are part of its five protein com-
plexes. Seven proteins belong to complex I, three proteins belong to complex III, two to com-
plex IV, and four proteins are subunits of complex V. I detected no protein subunit of com-
plex II. 
 
4.5.4 Identified membrane proteins 
 
In order to identify putative transmembrane proteins, I analyzed all of the identified proteins 
with a transmembrane prediction software (SOSUI), which predicts the transmembrane 
helices by calculating the hydrophobicity, the amino acid charges and the sequence length of a 
candidate peptide. Although about one third of the identified proteins are membrane-
associated proteins located either at the inner membrane (27 proteins) or at the outer 
membrane (two proteins) of the mitochondrion, only four of them are really transmembrane 
proteins with one or two transmembrane helices. These are spot 13 (GTP-specific succinyl-
CoA synthetase beta-subunit), spot 75 (NADH-ubiquinone oxidoreductase (complex I) B16.6 
kDa subunit), spot 90 (isocitrate dehydrogenase, gamma-subunit), and spot 134 (sideroflexin 
1). The location of these spots is highlighted in Fig. 4-14. 
fied to be a short isoform of 
ctin-beta. 
.5.6 Comparison of theoretical and the experimental pI and MW  
 
4.5.5 Multiple spot proteins 
 
A total of 17 proteins on the reference map could be detected in more than one spot (Fig. 4-
15). The majority of the multiple spot proteins are most probably isoforms, such as spots 9 
and 10 (HSP 60 kDa), spots 11 and 12 (actin-beta), spots 34 and 118 (succinyl CoA: 3-
oxoacid CoA transferase), spots 36 and 47 (ATP synthase, H+ transporting F1), spots 37, 123 
and 124 (medium-chain acyl CoA isomerase), spots 38 and 39 (similar to delta 3,5-delta 2,4-
deinoyl-CoA isomerase), spots 40 and 128 (electron-transfer-flavoprotein, alpha subunit), 
spots 48 and 49 (glutamate dehydrogenase 1), spots 50 and 51 (Tu translation elongation 
factor), spots 52 and 67 (acetoacetyl-CoA thiolase), spots 53 and 69 (voltage-dependent anion 
channel 1), spots 63 and 66 (complex III subunit II), spots 81 and 82 (isocitrate 
dehydrogenase), spots 85 and 87 (malate dehydrogenase 2), and spots 88 and 89 
(glyceraldehyde-3-phosphate dehydrogenase). Spots 5 and 31 (complex IV, subunit Va) 
correspond to same gene product but have markedly different pI and MW. Similar to that, spot 
114, which was identified by sequence information, corresponds to the same gene product as 
spots 11 and 12 (actin-beta). Spot 26 was at first identified as an unkown protein for 
(MGC:9832). After sequence alignment of the amino acids with the help of the protein-
BLAST program (see list of internet sites), it was finally veri
a
 
4
 
The theoretical pI and MW of proteins shown in my protein list were calculated with the 
“Compute pI/MW” tool of the SWISS-PROT database. This tool calculates the pI of a protein 
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ot # number
sp
number
by calculating the mean of the pK values of its amino acids as described by Bjellqvist et al.
(1993). The MW of a protein was calculated as the sum of the average isotopic masses of  
function  sp  of 
ots 
 of 
proteins 
mitochondrial  90 74 
respiratory chain  19 16  
complex I [6] [29] [30] [75] [126] [137] [138] 7 7 
complex II no   
complex III [25] [55] [63]/[66] 4 3 
complex IV [5]/[31] [56] 3 2 
complex V [3] [18] [36]/[47] [106] 5 4 
fat metabolism  19 13 
ß-oxidation  [28] [37]/[123]/[124] [38]/[39] 
[40]/[128] [52]/[67] [54] [65] [79] [92] 
[133]
15 10 
other proteins for fat 
metabolism 
/[118][34]  [45] [64] 4 3 
nucleotide metabolism  5 5 
 [61] [74] [93] [135] [130] 5 5 
protein metabolism  14 12 
 [20] [35] [43] [48]/[49] [50]/[51] [84] 
[91] [119] [122] [125] [127] [140]
14 12  
carbohydrate metabolism    
 [13] [15] [24] [27] [32] [60] [62] [80] 
[81]/[82] [83] [85]/[87] [90]
14 12 
transport proteins  10 7 
HSP  [7] [9]/[10] [33] [58] 5 4 
VDAC [53]/[69] 2 1 
TOM  [67/2] 1 1 
TIM [21]/[22] 2 1 
other functions  9 9 
cell protection [41] [72] [121] 3 3 
heme biosynthesis [68] 1 1 
apoptosis [44] 1 1 
sulfide oxidation  [132] 1 1 
iron transport [134] 1 1 
maintenance and cell growth [70] 1 1  
unknown [71] 1 1 
    
other compartments  15 11 
cytoplasmic  [11]/[12]/[26]/[114] [16] [86] [88]/[89] 
[96] [101] [120]
11 7 
endoplasmic reticulum ][1  [23] [42] 3 3  
B-cell-specific [103] 1 1 
    
location unknown  1 100  
function unknown [2] [46] [73] [105] [129] [131] [136] 7 7 
nucleotide metabolism [117] 1 1  
HSP  [8] [14] 2 2 
    
Total  115 95 
membrane proteins [13]  [75]  [90]  [134] 4 4 
 Tab. 4-1: Sorting of the identified proteins according to their subcellular locations and functions. Proteins
with transmembrane domains predicted by the SOSUI-algorithm are listed and highlighted separately. 
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location spot number protein number  percent 
mitochondrial total 90 74 77% 
M: mitochondria 31 27 28% 
MM: mitochondrial matrix 36 27 28% 
MIM: mitochondrial inner membrane 18 16 17% 
MOM: mitochondrial outer membrane 3 2 2% 
MIMS: mitochondrial intermembrane space 2 2 2% 
    
other compartments 15 11 12% 
C: cytoplasmic 11 7 8% 
ERL: endoplasmic reticulum lumen 3 3 3% 
cell: cell associated proteins 1 1 1% 
    
location unknown 10 10 11% 
    
Total 115 95 100% 
 
 
 
 
amino acids in the protein and the average isotopic mass of one water molecule. 
Tab. 4-2: Classification of the identified proteins according to their location. The mitochondrial group (M)
includes those proteins that are definitively mitochondrial but for which no further information exists on
their exact location. 
Fig. 4-13: Classification of the identified proteins according to their location. The mitochondrial group (M) 
includes those proteins that are definitively mitochondrial but for which no further information exists on 
their exact location. 
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 The experimental pI of each protein was calculated by using the regression formula that I had 
obtained from the measurement of the pH gradient (see section 4.3.1). Similar to that, the ex-
perimental MW was calculated with the regression formula derived from a series of MW stan-
dard markers. The correlation between the experimental and the theoretical pI and MW values 
was analyzed with the ANOVA statistics software (Fig. 4-16). The correlation between the 
coupled pI or MW values was tested by the coupled t-test. The correlation coefficient (R) of 
the coupled pI values is equal to 0.873 (p<0.0001) and that of the MW values is equal to 0.941 
(p<0.0001). The absolute differences between theoretical and experimental pI values are be-
tween 0.01 and 1.81 pH values. (median = 0.69 pH values, interquartile distance = 0.35 pH 
values). Similar to that, the absolute differences between theoretical and experimental MW 
values are between 0.08 to 43.09 kDa (median = 3.48 kDa, interquartile distance = 3.76 kDa).  
 
 
 
 
 
 
 
Fig. 4-16: Comparison of the theoretical and experimental pI and MW of the identified proteins. The left 
regression diagram depicts the relation of the pI values between the measured values (m) and the theoretical 
calculations (S). Similar to that, the right regression diagram depicts the relation between the two different
MW values. The linear regression formulas and the lateral dispersion (R2) are depicted below the diagrams. 
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5 DISCUSSION 
 
5.1 Choice of material 
 
The aim of this study was to establish a reference 2D-electrophoresis map of the human 
mitochondrial proteome that could be used in subsequent studies to identify patients with 
mitochondrial disease. I chose immortalized lymphoblastoid cells as the material to 
investigate. Compared to other possible materials like muscle cells and fibroblasts, 
lymphoblastoid cells can be more easily obtained from patients. Routinely, 5-10 ml 
heparinized whole blood are sufficient to establish a permanent cell culture. This procedure is 
more acceptable to parents and children as compared to muscle or skin biopsies. Lymphocytes 
can be cultured in vitro which allows the yield of enough material for my investigation. Since 
the cells can grow in suspension, high cell density can be obtained without too much 
expenditure of work and cost. Lymphoblastoid cells are transformed with Epstein-Barr Virus 
(EBV) for immortalization. EBV-transformation as compared to SV40-transformation has the 
advantage of higher chromosomal stability during subsequent passages [Jha et al., 1998]. 
Another advantage of lymphoblastoid cells is that they express a respiratory chain defect – in 
contrast to fibroblasts – more frequently [Bourgeron et al., 1993]. Although the number of 
mitochondria in lymphocytes (about 15-20/cell) is far lower than that in liver cells (2,200/cell 
[Rohr et al., 1976]), the easier access to lymphoblastoid cells compared to liver cells 
counterbalances this shortcoming.  
In recent years, several studies of the human mitochondrial proteome have been carried out on 
other materials like placental cells, transmitochondrial cybrids and neuroblastoma cell lines 
[Rabilloud et al., 1998 and 2002; Lopez et al., 2002; Fountoulakis et al., 2003]. However, for 
diagnostic purposes these cells are generally not available. In contrast, lymphoblastoid cells 
can be obtained from any patients at any age without anaesthesia. This also allows the study 
of mitochondrial proteins in normal control individuals at different age-groups in order to find 
out age-related changes. Additionally it also allows investigation of the genetic variability in a 
larger number of control patients at any given age. 
 
5.2 Mitochondrial isolation 
 
Isolation of mitochondria is the first step to investigate mitochondrial function in vitro and to 
analyze their proteome. Subfractionation of cellular components can intensify the low-
abundance proteins and make their detection easier. The effect of enrichment of mitochondrial 
proteins is illustrated in Fig. 4-3. The number of spots in the mitochondrial gel is distinctly 
reduced compared to that of the gel from whole lymphocyte proteins. The background noise 
and the complexity of the sample are thus reduced. This simplifies and focusses the study on 
the mitochondrial proteome. I have introduced several modifications to standard protocols in 
my experiment in order to solve some basic problems of mitochondrial isolation. First of all, 
in order to disrupt the cell membrane more easily, the use of digitonin is necessary. However, 
this membrane destabilizing agent disrupts membranes indiscriminately, i.e. the membrane of 
subcellular organelles can be attacked as well. Bronfman et al. (1998) found out that subcellu-
lar organelles are only affected if the concentration of digitonin is higher than 0.5-1.0 mg/ml. 
I therefore used only low concentrations of digitonin (0.1 mg/ml). The electron microscopic 
photographs of the mitochondrial pellet demonstrate that most of the mitochondria have intact 
inner and outer membranes. The slight swelling of the mitochondria may be due to the lower 
osmotic pressure of the used buffer. Secondly, I repeated the mechanical homogenizing cycle 
three times to insure the disruption of all cells. After the third round of homogenization about 
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 97% cells were disrupted. The number of repetitive homogenizing cycles depends not only on 
the type of biological material but also on the type of pestle and on the rotating speed of the 
homogenizer. Thirdly, I separated mitochondria from other subcellular organelles by centrifu-
gation on a discontinuous hybrid density gradient. Since the densities of mitochondria and 
lysosomes are very close to each other (1.11 g/ml of mitochondria versus 1.07 g/ml of ly-
sosomes), the separation of these two fractions is of special importance. For this task standard 
protocols suggest the use of a continuous Percoll gradient which forms during centrifugation. 
However, this method did not lead to a satisfactory result. Since the density-gradient was con-
tinuous, more than five bands were formed after centrifugation. Three of them were the mito-
chondrial bands and lay very close to each other. In addition the mitochondrial band was too 
broad. Therefore, it was difficult to assure the purity of the product, especially when the 
original material was limited. So I opted for a discontinuous gradient (35% and 17% metri-
zamide and 6% Percoll, with the densities 1.1304 g/ml, 1.1029 g/ml and 1.0331 g/ml), in or-
der to separate the mitochondria from the lysosomes sharply at two different interfaces. The 
electron microscopic photographs of the products from each interface confirmed that they 
contained the expected subcellular fractions. Disadvantage of the discontinuous gradient is the 
high cost of the metrizamide and the additional work to prepare the gradient. 
 
5.3 Two-dimensional electrophoresis 
 
5.3.1 The choice of carrier ampholytes for isoelectric focussing. 
 
I used carrier ampholytes for isoelectric focussing instead of commercially available 
immobilized pH-gradients. In Tab. 5-1 the advantages and disadvantages of these two 
methods are compared. Several advantages for my special task made me to use carrier 
ampholytes to run IEF-separations. A very good protein resolution can be expected by using 
ng  lo
 
 
Carrier ampholytes Immobilized pH-gradients 
excellent protein resolution  good protein resolution 
the pH-gradient may drift depending on the the pH-gradient is stable  
variable gel-lenghts can be prepared mercially available gel-lengths can be 
tes according to self preparation not possible 
atch differences present in self- , 
 in the 
commercially available ampholytes 
minor lot-to-lot differences in the precast gels 
he 
concentration of proteins and of salts of proteins espacially at high 
time of electrophoresis  
only com
chosen 
easy blending of a ampholy
the pH-range of interest 
special experience needed easier to handle 
good reproducibility (thin tube gels) 
batch-to-b
excellent reproducibility 
IPG-strips only commerically aveilable
cast gels 
minor lot-to-lot differences
therefore no batch-to-batch differences 
the pH- gradient can be influenced by t the pH-gradient can also be influenced by the 
concentration 
concentrations.   
the pI- resolution is 0.010 pH unit the pI- resolution is 0.016 pH unit 
 
 
 
Tab. 5-1: Comparison of carrier ampholytes and immobilized pH-gradients for first 
dimension isoelectric focussing. 
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 gradients of carrier ampholytes [Klose, 1999b; Lopez, 1999]. Secondly, variable pH ranges 
can be prepared by the blending of different ampholytes. In addition, the preparation of a tube 
gel is much easier than that of immobilized pH-gradients and does not require complex 
gradient casting equipment. However, a variable batch-to-batch reproducibility, the effect of 
protein concentration on the shape of the pH-gradient, and the cathodic drift of the pH-
gradient with time are some drawbacks.  
ation.  
niform. 
 
Since the aim of my study was to detect as many mitochondrial protein spots as possible, 
optimum resolution was paramount. I thus chose carrier ampholytes to run my IEF-
separations. On the other hand, the disadvantages of carrier ampholytes were minimized since 
I blended a large volume of gel stock-solution and aliquoted it into small portions so that all 
experiments were carried out with the same batch of ampholyte mixture. The cathodic drift of 
the pH-gradient with time was controlled by using a programmable power supply. This added 
to the standardization of IEF-running conditions. The effect of the protein sample on the pH-
gradient was also investigated and is discussed below. 
 
5.3.2 Reproducibility 
 
The reproducibility of 2D-separations can be assessed by three aspects: 
 
A) The presence/absence of spots: the reproducibility of protein resolution,  
B) The position of spots: the reproducibility of protein spot location on the gel and  
C) The quantity of spots: the reproducibility of protein abundance. 
 
In order to test the reproducibility of my gel-runs, I isolated mitochondrial proteins from the 
same cell line and run them on four different gels.  
 
A)  The gel-runs achieved a satisfactory reproducibility of protein resolution since each 
spot on one gel was reproduced on the other test-gels.  
 
B)  The reproducibility of position was only satisfactory when spots were compared to 
one another in a small perimeter of 3-5 cm from a certain anchor-point, i.e. the 
corresponding spots were only congruent when the gels were compared subsection 
by subsection. These running differences between two large gels might be due to 
minor inconsistencies of running conditions (temperature, buffer-composition), gel 
quality or protein-concentr
 
C)  Most of the protein spots achieved satisfactory quantitative reproducibility. However, 
the varying reproducibility of certain protein spots might be due to additional 
interfering factors. Spots 11 and 12, which correspond to the protein actin-beta, are 
examples. Since the test-samples of four gels were isolated from four different 
aliquots of the same cell line, the reproducibility of the mitochondrial isolation 
method was tested indirectly as well. The tight affiliation of actin-beta with the outer 
membrane of the mitochondria makes its removal difficult. The degree of actin-beta 
removal most probably depends on the cell fractionation process, which is the most 
difficult step to keep completely u
 
Several other factors can also impair the reproducibility. For example if the protein samples 
are thawed more than once not only the resolution of the protein spots but also their quantity 
is reduced (Fig. 4-8). This phenomenon is most probably due to the degradation of proteins 
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 during the freezing and thawing process. As expected the effect is most pronounced in low 
abundance proteins.  
 
5.3.3 The number of the visualized proteins on the gel 
 
In order to resolve as many protein spots as possible I used the large gel 2D-electrophoresis 
method with a length of 40 cm for isoelectric focussing [Klose, 1999b]. This way I separated 
420 protein spots on a silver stained 2D-electrophoresis gel. I do not know how far this 
number is from the actual mitochondrial protein content. Until now, a total of 525 different 
proteins have been registered in a special database of mitochondrial proteins (Human 
Mitochondrial Proteins Database). This database comprises information from “SwissProt”, 
“LocusLink”, “Protein Data Bank” (PDB), “GenBank”, “Genome Database” (GDB), “Online 
Mendelian Inheritance in Man” (OMIM), “Human Mitochondrial Genome Database” (mtDB), 
MITOMAP, and “Neuromuscular Disease Center and Mendelian Inheritance and the 
Mitochondrion” (MitoDat).  
4°C.  
roteins. 
Additionally, the existence of protein-isoforms increases the spot-number considerably. The 
number of isoforms of a certain protein varies between two to ten [Rabilloud et al., 1998; 
Jung et al., 2000; Fountoulakis et al., 2003]. Although not all spots of putative isoforms were 
analyzed in my study, from a representative sample of heat shock 60 kDa proteins (spot 9 and 
10) one can assume that the horizontal arrays of spots are isoforms of the same protein. In my 
sample, the number of isoforms of a protein ranged from two to six.  
Loss of proteins is doubtless taking place during the whole process from protein preparation 
until the staining of the gel. In order to minimize this loss I used a highly standardized sample 
preparation protocol introduced by Klose (1999a). One key point of this protocol is to 
solubilize hydrophobic proteins and keep them soluble. This is achieved by using CHAPS and 
high concentrations of urea to break up non-covalent interactions and by using DTT to break 
up disulfide-bridges. Another key point is to reduce protein degradation as good as possible. 
This is achieved by adding a cocktail of protein inhibitors and by performing all preparations 
in the cold at 
 
5.3.4 Staining of the gel 
 
In my experiments the silver stain was much more sensitive than the Coomassie stain. This 
has already been demonstrated in other studies [Switzer et al., 1979; Rabilloud, 1990; 
Shevchenko et al., 1996a]. On the other hand, for the purpose of protein identification by 
MALDI-TOF mass spectrometry the Coomassie stain seemed to be superior. None of my 
silver stained spots could be identified. However, this disappointing result might not be due to 
the silver stain itself but due to the fact that I only cut out those silver spots, which could not 
be identified on the Coomassie stained gel or which had been very weak. Therefore, the 
reason of the zero identification rate of my silver-stained spots was more likely to be caused 
by low protein abundance than by a strong influence of silver ions on the proteins. Other 
authors like Shevchenko (1996a) and Rabilloud (1998) have demonstrated that silver-stained 
gels can indeed be used for satisfactory mass spectrometric identification of p
 
5.4 Protein identification 
 
The proteins were identified mainly by MALDI-TOF mass spectrometry on the basis of their 
peptide mass fingerprints and in some cases by sequencing a peptide tag with MALDI-QTOF 
tandem mass spectrometry. 
According to the annotations in SWISS-PROT and NCBI, 78% of the identified proteins were 
human mitochondrial proteins. The other 22% identified proteins included 12% non-
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 mitochondrial proteins (cytoplasmic, endoplasmic reticulum or B-cell-associated) and 10% 
unknown proteins (most of them were only present as expressed sequence tags (EST)). The 
majority of my spectra was of good quality which allowed rather easy protein identification. 
The high accuracy in mass determination of the peptide fragments is made possible by 
MALDI-TOF mass spectrometry with “delayed extraction”. The delayed extraction method 
allows peptide fragments of the same weight to be better focused. This leads to sharp and ac-
curate spectra which allow the reliable identification of proteins even with limited sequence 
coverage [Jensen et al., 1996]. Therefore, my results were reliable even with low sequence 
coverage of around 12-17%. The array of identified proteins contained eleven proteins from 
other cell compartments. This “contamination” cannot simply be attributed to the purification 
method of the mitochondria. Such proteins as the B-cell associated protein (spot 103) are very 
abundant and/or specialized for the lymphoblastoid cells. These proteins are difficult to re-
move completely and are absent when mitochondria from other tissues were investigated (e.g. 
placenta [Rabilloud et al., 1998] or neuroblastoma cells [Fountoulakis et al., 2003]). How-
ever, I cannot rule out that these eleven proteins might interact with the mitochondria as well, 
since some other non-mitochondrial proteins are known to have very tight links to the mito-
chondria. They either bind to the outer membrane of mitochondria or transport material to the 
mitochondria. An example for these proteins is actin-beta, which is attached to the outer 
membrane of the mitochondrion and is involved in the movement of mitochondria within the 
cell.  
There are 25 spots in the list, which could not be identified. This might be due to the fact that 
the spectrum was not good enough or that the spectrum could not be matched with a protein 
from the databases. Besides the low abundance of certain proteins in the sample, several other 
reasons could also account for this. If two spots are very close to each other on the gel or 
overlapping each other, the proteins are mixed during excision of the spot. The spectra from 
those overlapping spots may confuse the database search. Peptide loss during the tryptic 
digest or the failure to extract the peptides from the gel pieces for MALDI-TOF mass 
spectrometry may be another reason for low amplitude mass spectra.  
ll fragment of actin-beta.  
Notably, a large part (72%) of the unidentified spots comprises small proteins whose 
molecular weights are below 17.5 kDa. Some of these proteins are fragments of larger 
proteins. Spot 114 is an example for that. This spot is the smallest protein among the 
identified ones. Its molecular weight is around 5-10 kDa and it could only be identified by 
protein ladder sequencing to be a sma
 
5.5 The mitochondrial proteome reference map  
 
I established a reference map of the mitochondrial proteome of human lymphoblastoid cells. 
This map will be used as a tool for further investigation of mitochondrial proteins of patients 
with mitochondrial diseases. A total of 95 proteins, 74 of them of sure mitochondrial origin, 
have been identified on this reference map (Fig. 4-12). The sub-mitochondrial location and 
the function of each identified mitochondrial protein were looked up in various databases and 
original publications.  
 
5.5.1 The identified membrane proteins 
 
Similar to previous analyses of the mitochondrial proteome [Jung et al., 2000; Lopez et al., 
2000; Fountoulakis et al., 2003], most of my identified proteins are hydrophilic or easy to 
solubilize proteins. Although 18 proteins of the list were annotated to be membrane-
associated proteins, only four of them were clearly transmembrane proteins with at least one 
transmembrane helix.  
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 Unfortunately none of the mtDNA-encoded proteins could be identified in my study. The mi-
tochondrion is rich in membrane-associated proteins. Most of the 13 mtDNA-encoded pro-
teins are components of multi-protein-complexes and are located at the inner mitochondrial 
membrane. Analysis of putative transmembrane domains in these 13 proteins with the SO-
SUI-algorithm revealed that all of them are transmembrane proteins. If the proteome-map is 
to be used to elucidate mitochondrial diseases, the representation of membrane-proteins is 
paramount and has to be further worked on. 
 
The difficulty of the detection of membrane proteins seems to be connected to the principle of 
2D-electrophoresis. This method has certain limitations to detect four kinds of proteins [Gygi 
et al., 2000; Nordhoff et al., 2001]:  
 
A)  hydrophobic proteins,  
B)  proteins of multi-protein-complexes,  
C)  proteins with a very basic pI and  
D)  very small proteins  
 
The critical point for sufficient membrane-protein separation is the isoelectric focussing in the 
first dimension: 
 
A)  Since membrane proteins are mostly hydrophobic proteins, they need to be solubilized 
to make them migrate in an electric field. This can be achieved by detergents (e.g. SDS 
or CHAPS). These detergents, however, affect the isoelectric point of the protein 
[Rabilloud, 1996]. Therefore, only urea as a protein denaturant can be added to the 
isoelectric focussing gel to keep the proteins in solution. CHAPS, a zwitterionic 
detergent, is added to the sample buffer to facilitate the solubility of hydrophobic 
proteins during sample preparation. However, its effect subsides as soon as the 
proteins enter the IEF-gel. It seems that the urea in the IEF-gel can hardly counteract 
the tendency of the hydrophobic proteins to aggregate. Therefore, only a few 
membrane-proteins maintain their solubility and migrate towards their isoelectric 
points. The rest of the membrane proteins seem to aggregate and do not even enter the 
IEF-gel. 
B) 
es into multi-protein 
aggregates that cannot migrate though the pores of the 3.5% polyacrylamide IEF-gel.  
C) 
 the loss of 
the very basic proteins unless they are captured in a higher percentage cap-gel. 
D) 
 
The proteins that are part of multi-protein-complexes are also denatured and 
solubilized by the use of CHAPS and urea during sample preparation. When the 
proteins enter the IEF-gel the effect of CHAPS begins to subside and some of the 
proteins start to refold and partially reconstitute themselv
 
If the proteins have a very basic pI (>10) which is often the case for membrane 
proteins, they do not focus properly in the IEF-gel. At the basic end of the IEF-gel the 
pH gradient does not reach its equilibrium [Klose, 1995]. This would cause
 
Small proteins with a molecular weight below 10 kDa are difficult to detect [Klose, 
1995]. This is due to the fact that the pores of the 15% second dimension SDS-PAGE-
gel are too large to focus the small proteins properly [Carroll et al., 2002]. For proteins 
of this size a polyacrylamide-percentage of 20-22% would be appropriate. This could 
be achieved by pouring a 5-20% gradient-gel. This procedure is very laborious and 
difficult to reproduce exactly. It would make different second dimension separations 
difficult to compare. Beyond that, the small proteins fail to stain with Coomassie blue. 
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 This is due to their low absolute peptide content despite the fact that they might be 
present in the same molar range as high molecular weight proteins. Even if they can be 
detected on Coomassie stained gels they might be difficult to identify via MALDI-
TOF mass spectrometry since there are only few peptide fragments available for a 
peptide fingerprint analysis. In this case one has to resort to the sequence determina-
tion of a peptide fragment by MALDI-QTOF tandem mass spectrometry. 
r isoelectric focussing. [Rabilloud et al., 1996, 1999; Henningsen et al., 2002; 
avarre et al., 2002] 
.5.2 Multiple spots proteins 
ge). Most of them (n = 15) 
re present in pairs and are probably isoforms of the same protein.  
he isoforms could be subdivided into: 
• nslational 
modification of proteins, such as phosphorylation, glycosylation or acetylation  
• 
lamide with SH-groups or by oxidation of methionin 
residues during sample preparation. 
r, they 
ight well cause a shift of the isoelectric points either to the acidic or to the basic side. 
recursor-mRNA. Proteolysis during the whole 
rocedure might be another possible reason.  
.5.3 Comparison of my results with other mitochondrial proteomic projects 
nt in 
 
The under-representation of transmembrane-proteins on a regular 2D-gel is a severe drawback 
of the method. Further work has to be done to make these proteins more soluble and 
accessible fo
N
 
5
 
17 proteins in my list are represented by multiple spots (2-3 in avera
a
 
T
 
Naturally occurring isoforms that are formed by any kind of in vivo post-tra
 
Isoforms caused by artifacts during sample preparation, which might be generated by the 
reaction of unpolymerized acry
 
These modifications do not change the molecular weight of a protein so much that a 
difference in molecular weight might be detected in the second dimension run. Howeve
m
 
I also found proteins that were present in multiple spots and differed considerably in 
molecular weight and/or isoelectric point: COXA (spots 5 and 31), mitofilin (spots 20 and 21), 
and actin-beta (spots 11,12, 26 and 114). The large differences in molecular weight could be 
caused by differential splicing of the same p
p
 
5
 
Two groups have established a human mitochondrial proteome database before. One is 
Rabilloud et al. (1998 and 2002) who investigated mitochondria from human placenta. The 
other group is Fountoulakis et al. (2003) who analyzed mitochondria from a human 
neuroblastoma cell line IMR-32. The database of Rabilloud et al. (2002) contains 68 proteins 
in total. The other database of Fountoulakis et al. (2003) contains 185 different proteins. I re-
identified 29 proteins in Rabilloud’s database and 65 in Fountoulakis’ database (Fig. 5-1). 
Excitingly, in comparison to these two databases, I identified 26 new proteins. 54% of them 
are of definitive mitochondrial origin. 35% of them were unidentified proteins only prese
EST databases. Interestingly, three of my four transmembrane proteins were identified for the 
first time.  
Similar to my experience, Rabilloud’s and Fountoulakis’ databases do not include many 
transmembrane proteins either. Using the SOSUI-algorithm, I controlled all the proteins in 
Rabilloud’s database. Only two proteins in this database carry transmembrane domains. A 
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 similar check was done with the proteins from Fountoulakis’ database, which carried a 
SWISS-PROT accession number. None of these proteins had a transmembrane domain. None 
of the mtDNA-encoded proteins were identified in both databases either. Since their experi-
ents were carried out with the same methods, the limitation and drawbacks of the 2D-m
electrophoresis become clear.  
 
 
 
 
MW  
 
R = 0.873 and a lateral dispersion 
f R = 0,762. The proteins with a large difference between experimental and theoretical pI 
 
• 
as impossible to 
 
 
Fig. 5-1: Comparison of my results to
Rabilloud‘s and Fountoulakis‘
mitochondrial proteome databases.
Compared to the 95 proteins in my
database, the database of Rabilloud
contains 68 proteins in total and the other
database contains 185 different proteins.
The shared proteins between the different
databases are depicted in the overlaying
t
5.5.4 Comparison of the theoretical and the experimental pI and 
5.5.4.1 Comparison of the experimental pI and the theoretical pI 
 
The correlation between experimental and theoretical pI values in my study is not as thight as 
described by other authors (Bjellqvist et al., 1993; Perrot et al., 1999). However, the 
correlation between the experimental and the theoretical pI still tends to lie on a linear 
regression line (Fig. 4-16) with a correlation coefficient of 
2 o
values were studied separately. They fall into the following catagories:  
Most of the mitochondrial proteins are nuclear encoded. They are synthesized in the 
cytosol as preproteins with a N-terminal transit sequence of about 20-30 amino acids. 
After import into the mitochondrion this transit-sequence is cleaved and the proteins fold 
into its mature conformation. Therefore, most mitochondrial proteins in my 2D-map are 
assumed to be mature proteins. The site of cleavage has not been determined 
experimentally for most of the proteins and in the databases it is generally only calculated 
from primary characteristics of mitochondrial import sequences [Claros et al., 1996]. In 
some proteins of my database (n = 7) the putative cleavage point w
determine by calculation. The calculation of pI of these seven proteins therefore only 
takes into account the pre-protein sequences. The pI is thus wrongly shifted towards the 
basic side. 
• For seven proteins in my database only ESTs were available in the public databases. Since 
ESTs might be incomplete or encode a pre-protein, the theoretical MW and pI of the EST 
derived proteins were unraliable.  
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 • 
is or phosphrylation and might cause a substantial 
• 
 not linear any more close to its 
• rtifacts (e.g. partial hydrolysis by proteases) might cause protein 
degeneration. The ensuing fragments run differently on the 2D-gel than the intact proteins 
oretical and the 
experimental pI-values. 
e marker set which 
only spanned the range betweeb 17.5 kDa and 76 kDa. Therefore, the MW of the proteins 
could not be determined with certainty when they run below 17.5 kDa or above 76 kDa. It is 
exactly these proteins which deviated most from the regeression line (Fig. 4-16).  
Variation in protein expression patterns might be due to alternative splicing events on 
mRNA-level or due to post-translational modification. These modifications may be due to 
glycolysation, partial hydrolys
difference between the experimental pI value and the theoretical one. This was verified by 
the fact that eight of those obviously deviating spots (pI-difference >1.00 pH unit) were 
found to be isoforms of four proteins.  
By direct measurement, the linearity of the pH-gradient in the IEF-gel could only be 
verified between pH 5-9. The pH-gradient of the IEF-gel is
basic end. Therefore, the experimental pI values of those proteins focussing at the basic 
end were unreliable. This results in a pI-difference larger than 1.00 pH unit for almost all 
the basic proteins whose theoretical pI is larger than pH 9.00. 
Preparation a
and might be as well a reason for lager deviations between the the
 
5.5.4.2 Comparison of the experimental MW and the theoretical MW 
 
The correlation of experimental and theoretical molecular weights is better (correlation 
coefficient: R = 0.941) than that of the isoelectic points. The values lie on a regression line 
with a lateral dispersion of R2=0.885. In my study I used a mass referenc
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6 CONCLUDING REMARKS  
 
The establishment of a reference mitochondrial proteome map of human lymphoblastoid cells 
provides a basic and useful tool for researchers working in the field of mitochondrial diseases. 
This 2D-reference map displays a different subset of proteins as compared to total cell 
homogenates and gives an overview of the proteins present in the mitochondria.  
s. 
tion.  
 
This reference map makes it possible to look for abnormal expression of mitochondrial 
proteins in patients with mitochondrial disease
 
However, there are still many unsolvend problems remaining. The major problem is the 
limited identification rate of membrane proteins. The separation of these proteins is especially 
important for researchers in the mitochondrial field, since one can assume that the double 
membrane structure of the mitochondrion carries many transmembrane proteins. Therefore 
improvements of the 2D-electrophoresis should be especially focussed on the resolution of 
membrane proteins. The identification of mtDNA-encoded proteins is another difficult task 
that I chose for my further research.  
 
Another major task for further study is to elucidate the variability (e.g. the polymorphisms) of 
mitochondrial protein expression patterns in healthy controls. This implies a lot of routine 
work, however it is doubtless very important. Whether a deviating protein pattern has a 
meaning for pathophysiology can only be verified based on thorough studies of the variation 
in the normal popula
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 SUPPLEMENTARY MATERIAL 
 
On the following pages the 12 subsections of Fig. 4-12 are depicted in greater detail with 
protein labels. The numbers in brackets refer to the protein number of the list depicted in Tab. 
7-1. 
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 Fig. 4-12#1: Section 1 of mitochondrial the proteome ma64 
  
 
 
 
 
 
 
 
Fig. 4-12#2: Section 2 of the mitochondrial proteome map 
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Fig. 4-12#3: Section 3 of the mitochondrial proteome map 
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 Fig. 4-12#4: Section 4 of the mitochondrial proteome ma67 
  
 
 
 
 
 
 
 
 Fig. 4-12#5: Section 5 of the mitochondrial proteome map68 
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 Fig. 4-12#6: Section 6 of the mitochondrial proteome ma69 
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 Fig. 4-12#7: Section 7 of the mitochondrial proteome ma70 
  
 
 
 
 
 
 
 Fig. 4-12#8: Section 8 of the mitochondrial proteome map71 
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 Fig. 4-12#9: Section 9 of the mitochondrial proteome ma72 
  
 
 
 
 
 
 
 
 Fig. 4-12#10: Section 10 of the mitochondrial proteome map73 
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74 Fig. 4-12#11: Section 11 of the mitochondrial proteome ma
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 Fig. 4-12#12: Section 12 of the mitochondrial proteome ma75 
  
Spot 
Nr. 
gene name Protein  name swiss ID SWISS_ 
PROT Nr. 
OMIM No. gi E.C. MW(S) pI 
(S) 
MW(m) pI(m) Seq. matched peptide     
(total peptide) 
sequence 
coverage %
probability 
based Mowse 
score 
Function location 
1 HSPA5 BiP protein. (HSP 70kDa protein 5) (glucose regulated protein 78 kDa, 
precusor) (GRP78 ) 
GR78_ HUMAN P11021 138120 6470150  70478,57 5,01 59100 5,20 19 - 
654 
10(17) 17 105 HSP(assembly)  endoplasmic 
reticulum 
lumen 
2 TUBB5 tubulin, beta 5. TBBX_ HUMAN P04350 602662 18088719  49630,87  51200 5,00  7(15) 16 67 ? ? 
3 ATP5B ATP synthase, beta chain, mitochondrial precursor. ATPB_ HUMAN P06576 102910 114549 3.6.3.14 51769,25  47900 5,20 48 - 
529 
28(60) 58 215 Complex V M 
4  not identified                
5 COX5A cytochrome C oxidase, subunit Va. COXA_ 
HUMAN 
P20674 603773 18999392 1.9.3.1 12513,23  13000 4,80 42 - 
150 
8(45) 28 64 Complex IV MIM 
6 NDUFS1 NADH-ubiquinone dehydrogenase, Fe-S protein 1. (75kDa) (NADH-ubiquinone 
oxidoreductase 75 kDa subunit, mitochondrial precursor) (Complex I-75kDa) 
(CI-75kDa) (NADH-coenzyme Q) 
NUAM_ 
HUMAN 
P28331 157655 13637608 1.6.5.3   
1.6.99.3 
77053,44  59100 5,80 24-
727 
16(29) 30 147 Complex I MIM 
7 HSPA9B heat shock 70kDa  protein 9B. (mortalin-2) (stress-70 protein, mitochondrial 
precursor) (75 kDa glucose regulated protein) (GRP 75) (Peptide-binding 
protein 74) (PBP74) (Mortalin) (MOT) 
GR75_ HUMAN P38646 600548 4758570  68759,00  57900 5,90 47-
679  
23(44) 36 215 HSP (apoptosis and 
chaperone) 
M 
8 HSPA8 heat shock 70kDa  protein 8. (HSP73) (heat shock cognate 71 kDa protein) HS7C_ HUMAN P11142 600816 5729877  70898,09  56400 5,70  14(20) 24 135 HSP ? 
9 HSPD1 heat shock 60kDa  protein 1,mitochondrial precursor. (chaperonin) (Hsp60) 
(CPN60) (heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) 
(P60 lymphocyte protein) (HuCHA60) 
CH60_  
HUMAN 
P10809 118190 14603309  57962,86  51400 5,70 27-
573 
33(99) 64 228 HSP (mitochondrial 
protein import and 
assembly) 
MM 
10 HSPD1 heat shock 60kDa  protein 1,mitochondrial precursor. (chaperonin) (Hsp60) 
(CPN60) (heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) 
(P60 lymphocyte protein) (HuCHA60) 
CH60_  
HUMAN 
P10809 118190 14603309  57962,86  51400 5,80 27-
573 
17(53) 36 124 HSP (mitochondrial 
protein import and 
assembly) 
MM 
11 ACTB actin, beta. (actin, cytoplasmic 1) ACTB_ HUMAN P02570 102630 14250401  41605,54  42700 5,60 2 - 
375 
16(63) 44 92  cytoplasmic 
12 ACTB actin, beta. (actin, cytoplasmic 1) ACTB_ HUMAN P02570 102630 14250401  41605,54  42900 5,70 2 - 
375 
9(30) 23 70  cytoplasmic 
13 SUCLG2 GTP-specific succinyl-CoA synthetase, beta subunit. (Succinyl-CoA ligase 
[GDP-forming] beta-chain, mitochondrial precursor) (Succinyl-CoA synthetase, 
betaG chain) (SCS-betaG)  
SCB2_ HUMAN Q96I99 603922 3766199 6.2.1.4 42564,92  42200 5,80 38-
432 
6(24) 15 MS-FIT citric Cycle M (membrane 
protein) 
14    --- HSPC108 Q9P042 Q9P042    --- 6841440  37145,40  41000 5,80  6(20) 28 68 HSP ? 
15 PDHB pyruvate dehydrogenase, E1-beta subunit mitochondrial precursor.  (PDHE1-B) ODPB_ 
HUMAN 
P11177 179060 387010 1.2.4.1 35890,39  35800 5,90 31 - 
359 
9(29) 30 72 Pyruvate complex MM 
16 PHB prohibitin PHB_  HUMAN P35232 176705 4505773  29804,10  29000 5,80  11(43) 58 119 regulation 
proliferation 
cytoplasmic 
17  not identified                
18 ATP5H ATP synthase H+ transporting,mitochondrial F0 complex, subunit d. (ATP 
synthase D chain, mitochondrial ) 
ATPQ_ 
HUMAN 
O75947    --- 5453559 3.6.3.14 18360,02  23100 5,50  16(39) 77 201 Complex V M 
19  not identified                
20 PRSS15 lon protease-like protein. (Lon protease homolog, mitochondrial precursor) 
(LONP) (LONHs) 
 LONM_ 
HUMAN  
P36776 605490 414046 3.4.21.- 102825,51  67200 6,20 ?-
959 
11(47) 15 70 AA metabolism MM 
21 HMP inner membrane protein, mitochondrial. (mitofilin) (motor protein) IMMT_HUMAN Q16891    --- 5803115  83626,35  62000 6,10 758 5(16) 12 ProFound 
1.0e+000 
(Z1.55) 
TIM MIM 
22 HMP inner membrane protein, mitochondrial. (mitofilin) (motor protein) IMMT_HUMAN Q16891    --- 5803115  83626,35  61200 6,10 758 17(32) 28 177 TIM MIM 
23 PDIA3 glucose regulated protein, 58kDa. (protein disulfide isomerase A3 precursor ) 
(disulfide isomerase ER-60) (ERp60) (58 kDa microsomal protein) (p58) 
(ERp57) (58 kDa glucose regulated protein) 
PDA3_ HUMAN P30101 602046 20127473  5.3.4.1 54265,22  51000 6,10 25-
505  
14(47) 26 105  endoplasmic 
reticulum 
lumen  
24 DLST dihydrolipoamide succinyltransferase component of 2-oxoglutarate 
dehydrogenase, mitochondrial precursor. (E2) (E2K). 
ODO2_ 
HUMAN 
P36957 126063 1709442 2.3.1.61 41349,64  48500 6,00 68-
453 
12(34) 22 73 citric cycle M 
25 UQCRC1 ubiquinol-cytochrome C reductase core protein I. (ubiquinol-cytochrome C 
reductase complex, core protein I, mitochondrial  precursor ) 
UCR1_ 
HUMAN 
P31930 191328 4507841  1.10.2.2  49101,57  44300 6,00 35-
480 
16(54) 27 94 complex III MIM 
26    --- unknown. (protein for MGC:9832) (actin, beta) Q96E67 Q96E67    --- 15277503  40220,13  41400 6,00 360 9(20) 28 100  cytoplasmic 
27 IDH3A isocitrate dehydrogenase 3 (NAD+), alpha. (isocitrate dehydrogenase [NAD], 
subunit alpha, mitochondrial precursor) (isocitric dehydrogenase) (NAD+-
specific ICDH) 
IDHA_ HUMAN P50213 601149 5031777  1.1.1.41 36640,21  38700 6,00 28-
366 
10(21) 22 94 citric cycle  M 
28 ECHS1 mitochondrial short-chain enoly-CoA hydratase 1, precursor. (enoyl-CoA 
hydratase, mitochondrial precursor) (SCEH) (enoyl-CoA hydratase 1) 
ECHM_ 
HUMAN 
P30084 602292 12707570  4.2.1.17 28354,66  27600 6,00  28-
290 
15(34) 44 149 ß-oxidation MM 
29 NDUFV2 NADH-ubiquinone oxidoreductase 24 kDa subunit, mitochondrial precursor. 
(24-kDa subunit of complex I) 
NUHM_ 
HUMAN 
P19404 600532 3123721 1.6.5.3  
1.6.99.3 
23760.31 5,71 24500 6,00 33-
249  
9(19) 30 95 Complex I MIM 
  
Spot 
Nr. 
gene name Protein  name swiss ID SWISS_ 
PROT Nr. 
OMIM No. gi E.C. MW(S) pI 
(S) 
MW(m) pI(m) Seq. matched peptide   
(total peptide) 
sequence 
coverage %
probability 
based Mowse 
score 
Function location 
30 NDUFA5 NADH ubiquinone oxidoreductase 13 kDa-B subunit. (complex I-13kDa-
B)(complex I subunit B13) 
NUFM_HUMAN Q16718 601677 2499316 1.6.5.3  
1.6.99.3 
13327,50  12100 5,80    sequence Complex I MIM 
31 COX5A cytochrome C oxidase, subunit Va. (cytochrome c oxidase polypeptide Va, 
mitochondrial  precursor) 
COXA_ 
HUMAN 
P20674 603773 18999392 1.9.3.1  12513,23 4,88 11400 6,00 42-
150 
6(21) 28 69 Complex IV MIM 
                  
32 OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase. (lipoamide) (2-oxoglutarate 
dehydrogenase E1 component, mitochondrial  precursor) (alpha-ketoglutarate 
dehydrogenase) 
ODO1_ 
HUMAN 
Q02218 203740 20541592 1.2.4.2 108880,11  67000 6,50 41-
1002 
13(17) 16 133 citric cycle  MM 
33 TRAP1 heat shock 75kDa protein, mitochondrial  precursor. (HSP 75) (tumor necrosis 
factor type 1 receptor associated protein) (TRAP-1) (TNFR-associated protein 
1) 
TRAL_ HUMAN Q12931 606219 2865466  80010,86 8,05 57500 6,40 ?-
704  
21(47) 39 180 HSP (chaperone) M 
34 OXCT succinyl CoA: 3-ketoacid CoA transferase, mitochondrial precursor. (succinyl 
CoA:3-oxoacid CoA transferase) 
SCOT_ 
HUMAN 
P55809 245050 4557817 2.8.3.5 52089,89  51300 6,10 40-
520 
11(19) 25 87 fat metabolism MM 
35 MCCC2 methycrotonoyl-CoA carboxylase 2 (beta) mitochondrial precursor. (non-biotin 
containing subunit of 3-methylcrotonyl-CoA carboxylase) (biotin carboxylase) 
(3-methylcrotonyl-CoA carboxylase 2) (MCCase, beta subunit) (3-
methylcrotonyl-CoA:carbon dioxide ligase, beta subunit) 
MCCB_ 
HUMAN 
Q9HCC0 210210 11545863  6.4.1.4 61333,20 7,58 50000 6,60 ?-
563 
14(42) 26 99 AA metabolism MM 
36 ATP5A1 ATP synthase, H+transporting, mitochondrial  F1 complex, alpha subunit, 
isoform 1, cardiac muscle 
ATPA_ HUMAN P25705 164360 4757810 3.6.1.34 55209,32  47900 6,60 44-
553 
21(45) 43 214 complex V MIM 
37 ACADM medium-chain acyl-CoA dehydrogenase, mitochondrial precursor. ACDM_ 
HUMAN 
P11310 607008  
201450 
2392312 1.3.99.3 43642,89  41800 6,25 26-
421 
17(43) 41 173 ß-oxidation MM 
38 ECH1 similar to delta3,5-delta2,4-dienoyl-CoA isomerase, mitochondrial ECH1_ HUMAN Q13011 600696 11433007 5.3.3.- 35994,34  31600 6,00 ?-
328 
12(29) 44 151 ß-oxidation M 
39 ECH1 similar to delta3,5-delta2,4-dienoyl-CoA isomerase, mitochondrial ECH1_ HUMAN Q13011 600696 11433007 5.3.3.- 35994,34  31600 6,10 ?-
328 
15(49) 41 112 ß-oxidation M 
40 ETFA chain A, three-dimensional structure of human electron transfer flavoprotein. 
(electron transfer flavoprotein alpha-subunit, mitochondrial  precursor) (alpha-
ETF) 
ETFA_ HUMAN P13804 231680 2781202  35079,57  32300 6,20 ?-
333 
10(25) 40 109 ß-oxidation MM 
41 PRDX3 peroxiredoxin 3. (thioredoxin-dependent peroxide reductase, mitochondrial  
precursor) (antioxidant protein 1) (AOP-1) (MER5 protein homolog) (HBC189) 
(PRX III) 
PDX3_ HUMAN P30048 604769 14250063  21468,45  25400 6,00 63-
256 
5(17) 21 MS-Fit  
ProFound 
(1.0e+000) 
cell protection M 
42 HADH2 hydroxyacyl-CoA dehydrogenase, type II. (type II HADH) (endoplasmic 
reticulum-associated amyloid beta-peptide binding protein) (short-chain type 
dehydrogenase/reductase) (XH98G2) 
HCD2_ 
HUMAN 
Q99714 300256 4758504 1.1.1.35 26923,08  25500 6,10 261 11(37) 58 157 in Alzheimer' disease endoplasmic 
reticulum 
lumen  
43 MCCC1 methylcrotonyl-CoA carboxylase alpha chain, mitochondrial precursor. (3-
methylcrotonyl-CoA carboxylase 1) (MCCase alpha subunit) (3-methylcrotonyl-
CoA:carbon dioxide ligase, alpha subunit) 
MCCA_ 
HUMAN 
Q96RQ3 210200 13518228 6.4.1.4 75030,63  59400 7,00 48-
725 
8(14) 16 82 AA metabolism MM 
44 PDCD8 programmed cell death 8. (apoptosis-inducing factor) PCD8_ HUMAN O95831 300169 4757732 1.-.-.- 55699,48  58200 7,00 103-
613 
11(29) 25 120 Apoptosis MIMS 
45 DLD dihydrolipoamide dehydrogenase, mitochondrial precursor DLDH_ 
HUMAN 
P09622 246900  
238331 
181575 1.8.1.4 50147,55  51500 6,90 36-
509 
7(19) 22 84 fat metabolism MM 
46    --- unknown. (protein for MGC 14085) Q96I46 Q96I46    --- 14043738  51905,08  49800 6,70 468 11(22) 28 118 ? ? 
47 ATP5A1 ATP synthase, H+transporting, mitochondrial F1 complex, alpha subunit. (ATP 
synthase alpha chain, mitochondrial precursor) 
ATPA_ HUMAN P25705 164360 4757810 3.6.3.14 55209,32  48100 6,80 44-
553 
27(39) 50 273 Complex V MIM 
48 GLUD1 chain A, structure of human glutamate dehydrogenase-Apo form. (glutamate 
dehydrogenase 1, mitochondrial precursor) (GDH) 
DHE3_ HUMAN P00367 138130  
606762 
4885281 1.4.1.3 56008,68  49500 7,00 54-
558 
18(30) 31 165 AA metabolism MM 
49 GLUD1 chain A, structure of human glutamate dehydrogenase-Apo form. (glutamate 
dehydrogenase 1, mitochondrial precursor) (GDH) 
DHE3_ HUMAN P00367 138130  
606762 
20151189 1.4.1.3 56008,68  49800 7,00 54-
558  
21(41) 33 159 AA metabolism MM 
50 TUFM Tu translation elongation factor, mitochondrial precursor. (elongation factor Tu, 
mitochondrial precursor) (P43) 
EFTU_ HUMAN P49411 602389 4507733  45045,00  42700 6,80 44-
452 
12(23) 26 132 protein synthesis M 
51 TUFM Tu translation elongation factor, mitochondrial precursor. (elongation factor Tu, 
mitochondrial precursor) (P43) 
EFTU_ HUMAN P49411 602389 4507733  45045,00  42600 6,90 44-
452 
23(41) 50 242 protein synthesis M 
52 ACAT1 mitochondrial  acetoacetyl-CoA thiolase. (acetyl-CoA acetyltransferase, 
mitochondrial  precursor) 
THIL_ HUMAN P24752 203750 499158 2.3.1.9 41386,02  41450 6,90 34-
427 
11(23) 31 109 ß-oxidation M 
53 VDAC1 voltage-dependent anion channel 1. (voltage-dependent anion-selective 
channel protein 1) (VDAC-1) (hVDAC1) (outer mitochondrial membrane protein 
porin 1) (plasmalemmal porin) (Porin 31HL) (Porin 31HM) 
POR1_ 
HUMAN 
P21796 604492 4507879  30641,40  35300 6,70 282 16(28) 67 226 VDAC MOM 
54 ETFB electron-transfer-flavoprotein, beta polypeptide. (Beta-ETF) ETFB_ HUMAN P38117 130410 4503609  27843,61  29100 6,40 255 7(24) 28 81 ß-oxidation MM 
55 UQCRFS1 ubiquinol-cytochrome C reductase iron-sulfur subunit, mitochondrial  precursor. 
(rieske iron-sulfur polypeptide 1) (rieske iron-sulfur protein) (RISP) 
UCRI_ HUMAN P47985 191327 5174743 1.10.2.2 21616,58  28300 6,30 79-
274 
6(24) 27 79 complex III MIM 
56 COX5B cytochrome c oxidase polypeptide Vb, mitochondrial precursor. COXB_ 
HUMAN 
P10606 123866 117103 1.9.3.1 10613,04 6,33 14500 6,40 32-
129 
6(17) 50 ProFound      
1.0e+00 
complex IV MIM 
  
Spot 
Nr. 
gene name Protein  name swiss ID SWISS_ 
PROT Nr. 
OMIM No. gi E.C. MW(S) pI 
(S) 
MW(m) pI(m) Seq. matched peptide   
(total peptide) 
sequence 
coverage %
probability 
based Mowse 
score 
Function location 
57  not identified                
58 HSPE1 chaperonin 10-related protein. (10 kDa heat shock protein, mitochondrial ) 
(HSP10) (10 kDa chaperonin) 
CH10_ HUMAN Q04984 600141 4028622  10800,50  11700 6,50 101 8(17) 71 150 HSP                  (mito 
protein biogenesis) 
MM 
59  not identified                
60 ACO2 aconitate hydratase, mitochondrial precursor. (aconitate hydratase) (citrate 
hydrolyase) (aconitase 2) (aconitase) 
ACON_ 
HUMAN 
Q99798 100850 5304852 4.2.1.3 82425,78  64100 7,20 28-
780 
28(55) 36 229 citric cycle  M 
                  
61 SHMT2 mitochondrial serine hydroxymethyltransferase. GLYM_ 
HUMAN 
P34897 138450 746436 2.1.2.1 52559,86  50300 7,30 30-
504 
24(52) 42 187 nucleotide 
metabolism 
M 
62 FH fumarate hydratase, mitochondrial precursor. (fumarase) FUMH_ 
HUMAN 
P07954 136850 
150800  
605839  
606812 
68293 4.2.1.2 50081,55  46100 7,20 45-
510 
12(29) 31 125 citric cycle  M 
63 UQCRC2 ubiquinol-cytochrome C reductase core protein II, mitochondrial precursor. 
(complex III, subunit II) 
UCR2_ 
HUMAN 
P22695 191329 12653427 1.10.2.2 46811,05  46100 7,20 15-
453 
13(41) 35 114 complex III MIM 
64 FDXR adrenodoxin reductase. (NADPH: adrenodoxin oxidoreductase, mitochondrial 
precursor) (AR) (Ferredoxin-NADP(+) reductase) 
ADRO_ 
HUMAN 
P22570 103270 178209 1.18.1.2 49967,33  48000 7,30 33-
491 
17(30) 37 203 fat metabolism MM 
65 ACAA2 acetyl-CoA acyltransferase 2. (mitochondrial  3-oxoacyl-CoA) (3-ketoacyl-CoA 
thiolase, mitochondrial ) (Beta-ketothiolase) (T1) 
THIM_ HUMAN P42765 604770 12804931 2.3.1.16 42039,29  47200 7,20 397 18(45) 49 187 ß-oxidation M 
66 UQCRC2 ubiquinol-cytochrome C reductase core protein II, mitochondrial precursor. 
(complex III, subunit II) 
UCR2_ 
HUMAN 
P22695 191329 12653427 1.10.2.2 46811,05  46200 7,20 15-
453 
12(35) 32 105 complex III MIM 
67 ACAT1 mitochondrial acetoacetyl-CoA thiolase. (acetyl-CoA acetyltransferase, 
mitochondrial  precursor) 
THIL_ HUMAN P24752 203750 499158 2.3.1.9 41386,02  42800 7,00 34-
427 
11(45) 36 114 ß-oxidation M 
67/2 TOM40 probable mitochondrial import receptor, subunit TOM40 homolog. (translocase 
of outer membrane 40 kDa subunit homolog) (Haymaker protein) (p38.5) 
OM40_ 
HUMAN 
O96008    --- 5174723  37893,10  43500 7,00 361 8(48) 27 72 TOM MOM 
68 CPO coprpoprphyrinogen III oxidase, mito precursor. (coproporphyrinogenase) 
(coprogen oxidase) (COX) 
HEM6_ 
HUMAN 
P36551 121300 547615 1.3.3.3 36853,89  41300 7,00 32-
354 
12(21) 32 145 heme biosynthesis M 
69 VDAC1 voltage-dependent anion channel 1. (voltage-dependent anion-selective 
channel protein 1) (VDAC-1) (hVDAC1) (outer mitochondrial membrane protein 
porin 1) (plasmalemmal porin) (Porin 31HL) (Porin 31HM)) 
POR1_ 
HUMAN 
P21796 604492 4507879  30641,40  35900 7,00 282 10(21) 43 141 VDAC MOM 
70 AK2 adenylate kinase 2 isoform A, mitochondrial. (adenylate kinase isoenzyme 2, 
mitochondrial) (ATP-AMP transphosphorylase) 
KAD2_ HUMAN P54819 103020 7524346 2.7.4.3 26346,55  30300 7,00 238 10(26) 37 135 maintenance and cell 
growth 
MIMS 
71 C21ORF33 anti-sigma cross-reacting protein homolog I beta precursor of human.  (ES1 
protein homolog, mitochondrial  precursor) (Protein KNP-I) (GT335 protein) 
ES1_  HUMAN P30042 601659 2134764  24016,57  27200 6,90 42-
268 
5(31) 43 64 ? M 
72 SOD2 superoxide dismutase [Mn], mitochondrial  precursor. (chain A,kinetic analysis 
of product inhibition in human manganese superoxide dismutase) 
SODM_ 
HUMAN 
P04179 147460 134665 1.15.1.1 22204,14  25300 6,70 25-
222 
9(15) 44 148 cell protection MM 
73    --- cDNA FLJ20420 fis, clone KAT02462. (hypothetical 26.2 kDa protein) (similar 
to hypothetical protein, FLJ20420) 
Q9NX63 Q9NX63    --- 8923390  26152,36  28500 7,00 227 6(20) 26 75 function? Skin? ? 
74 SSBP1 single-stranded DNA-binding protein, mitochondrial precursor. (Mt-SSB) 
(MtSSB) (PWP1-interacting protein 17) 
SSB_ HUMAN Q04837 600439 2624694  15195,14  15700 6,70 17-
148 
10(28) 70 138 nucleotide 
metabolism 
M 
75 GRIM19 NADH-ubiquinone oxidoreductase, B16.6 subunit. (complex I-B16.6) (CI-B16.6) 
(cell death-regulatory protein GRIM19) (CGI-39 protein) (gene associated with 
retinoic-interferon-induced mortality 19 protein) (GRIM-19) (CDA016) 
NB6M_ 
HUMAN 
Q9P0J0    --- 16923946 1.6.5.3  
1.6.99.3 
16567,12  16600 6,80 143 11(21) 66 166 Complex I MIM 
(membrane 
protein) 
76  not identified                
77  not identified                
78  not identified                
79 HADHA long-chain-fatty-acid beta-oxidation multienzyme complex, alpha chain, 
mitochondrial precursor. (trifunctional enzyme alpha subunit, mitochondrial  
precursor [includes: long-chain enoyl-CoA hydratase (EC 4.2.1.17); long chain 
3-hydroxyacyl-CoA dehydrogenase(EC 1.1.1.35)]) (TP-alpha) (78 kDa gastrin-
binding protein)  
ECHA_ 
HUMAN 
P40939 600890 543064 4.2.1.17   
1.1.1.35 
79009,87  62100 7,60 37-
763 
25(37) 34 225 ß-oxidation MM 
80 CS citrate synthase, mitochondrial precursor. CISY_ HUMAN O75390 118950 15302936 4.1.3.7 49000,22  47050 7,20 28-
466 
14(21) 22 126 citric cycle MM 
81 IDH2 isocitrate dehydrogenase [NADP] mitochondrial precursor. (oxalosuccinate 
decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) (ICD-M) 
IDHP_ HUMAN P48735 147650 20141568 1.1.1.42 46614,35  47100 7,40 40-
452 
15(23) 35 197 citric cycle  M 
82 IDH2 isocitrate dehydrogenase [NADP] mitochondrial precursor. (oxalosuccinate 
decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) (ICD-M) 
IDHP_ HUMAN P48735 147650 20141568 1.1.1.42 46614.35 8,32 47100 7,00 40-
452 
15(30) 38 173 citric cycle  M 
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83 IDH3B isocitrate dehydrogenase 3 (NAD+) beta, mitochondrial precursor. (isocitric 
dehydrogenase) (NAD+-specific ICDH) 
IDHB_ HUMAN O43837 604526 5901982 1.1.1.41 38793,79  46100 7,20 35-
385 
10(21) 28 95 citric cycle  M 
84 BCAT2 branched chain aminotransferase 2, mitochondrial. (branched-chain amino acid 
aminotransferase, mitochondrial precursor) (BCAT(m)) (placental protein 18) 
(PP18) 
BCAM_ 
HUMAN 
O15382 113530 4502375 2.6.1.42 39915,56  43900 7,00 352 11(22) 24 108 AA metabolism M 
85 MDH2 malate dehydrogenase 2, NAD, mitochondrial. MDHM_ 
HUMAN 
P40926 154100 5174541 1.1.1.37 33000,45  40800 7,00 25-
338 
8(25) 30 76 citric cycle  MM 
86 CRYZ crystallin, zeta. (quinone oxidoreductase) (NADPH:quinone reductase) QOR_ HUMAN Q08257 123691 13236495 1.6.5.5 35206,63  41900 7,00 329 6(26) 29 70 detoxication   Cytoplasmic 
87 MDH2 malate dehydrogenase 2, NAD, mitochondrial. MDHM_ 
HUMAN 
P40926 154100 5174541 1.1.1.37 33000,45  42400 7,00 25-
338 
14(36) 39 139 citric cycle MM 
                  
88 GAPD glyceraldehyde-3-phosphate dehydrogenase.  G3P2_ HUMAN P04406 138400 31645 1.2.1.12 35922,02  43500 7,00 334 10(17) 35 2.43 (1.0e+000)   Cytoplasmic 
89 GAPD glyceraldehyde-3-phosphate dehydrogenase.  G3P2_ HUMAN P04406 138400 7669492 1.2.1.12 35922,02  44100 7,10 334 11(27) 27 70   Cytoplasmic 
90 IDH3G isocitrate dehydrogenase. (isocitrate dehydrogenase [NAD] subunit gamma, 
mitochondrial precursor) (isocitric dehydrogenase) (NAD+-specific ICDH) 
IDHG_ HUMAN P51553 300089 12804901 1.1.1.41 38814,53  47100 7,20 40-
393 
5(21) 17 MS-Fit   citric cycle  M (membrane 
protein) 
91 GOT2 aspartate aminotransferase 2, mitochondrial precursor. (transaminase A) 
(glutamate oxaloacetate transaminase-2) 
AATM_ 
HUMAN 
P00505 138150 12739307 2.6.1.1 44695,28  43100 7,60 30-
430 
12(32) 27 97 AA transporter MM 
92 HADHSC short chain 3-hydroxyacyl-CoA dehydrogenase, mitochondrial precursor.             
(HCDH) (medium and short chain L-3-hydroxyacyl-CoA dehydrogenase) 
HCDH_ 
HUMAN 
Q16836 601609 2078329 1.1.1.35 32822,73  37700 7,00 13-
314 
12(24) 50 140 ß-oxidation MM 
93 AK3 adenylate kinase 4, mitochondrial. (adenylate kinase-4)  (AK4)  (ATP:AMP 
phosphotransferase)  
KAD4_ HUMAN P27144 103030 8051579 2.7.4.3 25268,00  32800 7,00 223 11(19) 34 153 nucleotide 
metabolism 
MM 
94  not identified                
95  not identified                
96 HBA1  hemoglobin, alpha chain. HBA_ HUMAN P01922 141800  
141850   
141860 
996122  15126,36  12700 7,10 141 5(10) 35 64   Cytoplasmic 
97  not identified                
98  not identified                
99  not identified                
100  not identified                
101 HBB hemoglobin, beta chain. HBB_ HUMAN P02023 141900   
603903 
122615  15867,22  10200 7,00 146   von sequence   Cytoplasmic 
102  not identified                
103 HBAP or REA B-cell associated protein. (B-cell receptor associated protein) (D-prohibitin)  Q99623 Q99623    --- 6005854  33296,38  35700 8,10 299 14(26) 51 161  B-cell 
104  not identified                
105 NIPSNAP1 NIPSNAP homolog 1. (4-nitrophenylphosphatase domain and non-neutonal 
SNAP25-like 1) 
NPS1_ HUMAN Q9BPW8 603249 4505399  33309,98  29900 8,00 284 9(22) 23 86 ? ? 
106 ATP5O ATP synthase H+ transporting, mitochondrial F1 complex, o subunit. 
(oligomycin sensitivity conferring protein) (human ATP synthase OSCP subunit, 
oligomycin sensitivity conferring protein) 
ATPO_ 
HUMAN 
P48047 600828 4502303 3.6.3.14 20875,49  26100 8,40 24-
213 
12(34) 47 110 Complex V MM 
107  not identified                
108  not identified                
109  not identified                
110  not identified                
111  not identified                
112  not identified                
113  not identified                
114 ACTB actin, beta. (actin, cytoplasmic 1) (fragment) ACTB_ HUMAN P02570 102630 16359158  41605,54  10200 8,10 2 - 
375 
  von sequence von sequence  Cytoplasmic 
115  not identified                
116  not identified                
117 PNPASE polynucleotide phosphorylase-like protein Q8TCS8 Q8TCS8    --- 20372922 2.7.7.8 85936,59  60500 6,50 783 14(20) 18 124 nucleotide 
metabolism 
? 
118 OXCT succinyl CoA: 3-ketoacid CoA transferase, mitochondrial precursor. (succinyl 
CoA:3-oxoacid CoA transferase) 
SCOT_ 
HUMAN 
P55809 245050 4557817 2.8.3.5 52089,89 6 51200 6,10 40-
520 
5(29) 16 MS-Fit fat metabolism MM 
119 PMPCA or 
MPPA or 
KIAA0123 
mitochondrial processing peptidase alpha subunit, mitochondrial precursor.         
(alpha-MPP) (P-55) (HA1523) 
MPPA_ 
HUMAN 
Q10713    --- 1709089 3.4.24.64 54624,57  50100 6,30 34-
525 
7(22) 16 MS-Fit and 
ProFound 
1.0e+000 
(Z1,77) 
regulation and 
assembly(Aa 
metabolism) 
MM 
  
Spot 
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120 LAP3 
orLAPEP 
cytosol aminopeptidase. (leucine aminopeptidase) (LAP) (leucyl 
aminopeptidase) (proline aminopeptidase) (prolyl aminopeptidase) 
AMPL_ 
HUMAN 
P28838    --- 12643394 3.4.11.1  
3.4.11.5 
52640,08  49400 6,20 488 9(15) 18 101 regulation and 
assembly(Aa 
metabolism) 
Cytoplasmic 
121 ALDH1B1 aldehyde dehydrogenase X, mitochondrial precursor. (ALDH class 2) DHA5_ HUMAN P30837 100670 399363 1.2.1.3 55292,03  48500 6,00 18-
517 
10(20) 27 105 detoxication of 
alcohol 
MM 
122 PMPCB mitochondrial processing peptidase beta subunit, mitochondrial precursor.           
(beta-MPP) (P-52)  
MPPB_ 
HUMAN 
O75439 603131 4758734 3.4.24.64 49487,50  44200 6,00 46-
489 
7(27) 17 63 protein regulation MM 
123 ACADM medium-chain acyl-CoA  dehydrogenase, mitochondrial precursor. ACDM_ 
HUMAN 
P11310 607008  
201450 
17440754 1.3.99.3 43642,89  41700 6,00 26-
421 
9(13) 20 131 ß-oxidation MM 
                  
124 ACADM medium-chain acyl-CoA dehydrogenase, mitochondrial precursor. ACDM_ 
HUMAN 
P11310 607008  
201450 
17440754 1.3.99.3 43642,89  41900 6,50 26-
421 
10(17) 25 121 ß-oxidation MM 
125 MRPS22 mitochondrial ribosomal protein S22. (gibt protein) (chromosome 3 open 
reading frame 5) (mitochondrial 28S ribosomal protein S22) (S22mt) (MRP-
S22) (GK002) 
RT22_ HUMAN P82650 605810 9910244  41280,38  39400 6,10 360 11(27) 23 97 ribosomal protein M 
126 NDUFS3 NADH-ubiquinone oxidoreductase 30 kDa subunit, mitochondrial precursor.         
(30-kDa subunit of complex I) (Complex I-30KD) (CI-30KD) 
NUGM_ 
HUMAN 
O75489 603846 5138999 1.6.5.3  
1.6.99.3 
26414,92  26500 5,90 37-
264 
15(26) 48 222 Complex I MIM 
127 TSFM elongation factor Ts, mitochondrial  precursor. (EF-Ts) (EF-TsMt) EFTS_HUMAN P43897 604723 12644268  30503,99  33200 6,30 46-
325 
3(38)  sequence protein synthesis M 
128 ETFA chain A, three-dimensional structure of human electron transfer flavoprotein. 
(electron transfer flavoprotein alpha-subunit, mitochondrial  precursor)  (alpha-
ETF) 
ETFA_ HUMAN P13804 231680 2781202  35079,57  33200 6,40 ?-
333 
6(25) 28 66 ß-oxidation MM 
129    ---  hypothetical protein FLJ113428. (cDNA FLJ11342 fis) (clone 
PLACE10108009)  
Q9NUJ1 Q9NUJ1    --- 8923001  33932,51  30600 6,60 306 6(20) 20 71 ? ? 
130 PYCR1 pyrroline-5-carboxylate reductase. (pyrroline-5-carboxylate reductase 1) 
(P5CR) (P5C reductase) 
PROC_ 
HUMAN 
P32322 179035 5902036 1.5.1.2 33374,65  34700 7,00 319 11(35) 31 84 Proline biosynthesis M 
131    --- similar to hypothetical protein FLJ10709. (hypothetical 72.6 kDa protein) Q9BUK4 Q9BUK4    --- 8922609  72600,98  57500 7,50 586 23(39) 40 258 ? ? 
132 SQRDL sulfide:quinone oxidoreductase, mitochondrial precursor SQRD_HUMAN Q9Y6N5    --- 10864011 1.-.-.- 49960,71  55700 7,60 ?-
450 
21(43) 47 218 mitochondrial  sulfide 
oxidation 
M 
133 HADHB trifunctional enzyme beta subunit, mitochondrial precursor, [Includes: 3-
ketoacyl-CoA thiolase; acetyl-CoA acyltransferase; beta-ketothiolase]. (TP-
beta)  
ECHB_ 
HUMAN 
P55084 143450 4504327 2.3.1.16 47484,90  53700 7,50 34-
474 
18(29) 31 154 ß-oxidation MM 
134 AFXN1 sideroflexin 1 SFX1_ HUMAN Q9H9B4    --- 20140250  35619,42  39600 7,30 322 7(17) 20 87 iron transport M (membrane 
protein) 
135 AKL3L adenylate kinase-3,mitochondrial. (adenylate kinase 3) (AK3) (AK3-alpha) 
(GTP:AMP phosphotransferase)  
KAD3_ HUMAN Q9UIJ7    --- 11130641 2.7.4.10 25434,22  30100 7,50 226 10(21) 50 154 nucleotide 
metabolism 
MM 
136 GBAS NIPSNAP2 protein. (glioblastoma amplified sequence) NPS2_ HUMAN O75323 603004 2769254  33742,64  30100 7,40 286 6(11) 16 70 ? ? 
137 NDUFB9 NADH-ubiquinone oxidoreductase, B22 subunit. (Complex I-B22) (CI-B22) NI2M_ HUMAN Q9Y6M9 601445 6274550 1.6.5.3  
1.6.99.3 
21699,72  28900 7,20 178 10(29) 46 109 complex I MIM 
138 NDUFB10 NADH-ubiquinone oxidoreductase, PDSW subunit. (Complex I-PDSW)                
(CI-PDSW) 
NIDM_ HUMAN O96000 603843 4758774 1.6.5.3  
1.6.99.3 
20645,48  27300 7,80 171 13(21) 47 145 complex I MIM 
139  not identified                
140 PPIF peptidyl-prolyl cis-trans isomerase, mitochondrial precursor. (PPIase) 
(rotamase) (peptidyl-prolyl isomerase F) (cyclophilin F) 
PPIF_ HUMAN P30405 604486 5031987 5.2.1.8 18897,38  20500 8,00 30-
207 
4(19) 33 sequence  assembly protein MM 
Tab. 7-1: The identified proteins of my study. Proteins from the mitochondrial fraction of human lymphoblastiod cells were extracted and separated by 2D-electrophoresis. The identification of proteins was carried out with 
MALDITOF and MALDI-QTOF mass spectrometry. The database search was performed with several search engines such as Mascot, ProFound, and MS-Fit. Information about a specific protein contains the spot number, the 
full name, the accession ID and SWISS-PROT number, the E.C. and gi numbers, the theoreticalMW and pI values from SWISS-PROT database [MW(S) and pI(S)] and the measuredMW and pI values [MW(m) and 
pI(m)].The data from the MS analysis i.e. the numbers of matching peptides and the probability of assignment of a random identity are listed here as well. 
M: mitochondrial; MM: mitochondrial matrix; MIM: mitochondrial inner membrane; MOM: mitochondrial outer membrane; MIMS: mitochondrial inter membrane space. 
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